

Olafur S. Palsson, Psy. D.

CURRICULUM VITAE

EMPLOYMENT

- May 2013-present **Professor of Medicine, UNC-Chapel Hill School of Medicine**
Division of Gastroenterology and Hepatology
- Aug. 2003-Apr. 2013 **Associate Professor of Medicine, UNC-Chapel Hill School of Medicine**
Division of Gastroenterology and Hepatology
- 2000-2003 **Research Associate, UNC-Chapel Hill School of Medicine**
Division of Digestive Diseases and Nutrition
- 1996-2000 **Director, Eastern Virginia Medical School Division of Behavioral Medicine**
Assistant Professor
Department of Psychiatry & Behavioral Sciences and
Department of Family & Community Medicine
Eastern Virginia Medical School, Norfolk, Virginia

EDUCATION

- July 1994-Sept. 1996 **Two-year Post-Doctoral Fellowship in Behavioral Medicine Research**
Department of Medicine, University of North Carolina at Chapel Hill
(dates of attendance: 7/1994-9/1996).
- December 1993 **Doctor of Clinical Psychology**
Virginia Consortium for Professional Psychology, Norfolk, Virginia
(dates of attendance: 8/1989-12/1993). APA Accreditation: Full
- May 1988 **Bachelor of Arts in Psychology, *summa cum laude***
University of North Carolina at Greensboro (dates of attendance: 1/1987-5/1988)
- 1983-1985 University of Iceland Medical School, Reykjavik, Iceland

DOCTORAL DISSERTATION: "The Psychological and Psychophysiological Effects of Stress Reduction by Means of a Group Hypnosis Intervention". Defended in August 1992, Eastern Virginia Medical School

INTERNSHIP IN CLINICAL PSYCHOLOGY: North Dakota Human Services, 2000 hours (1992-1993: Rotation 1 (6 months): North Central Human Service Center, Minot. Rotation 2 (6 months): North Dakota State Hospital, Jamestown

THIRD YEAR PREDOCTORAL CONCENTRATION IN CLINICAL PSYCHOLOGY:

1. Short-term psychodynamic therapy
2. The use of hypnosis in psychotherapy

OTHER PROFESSIONAL EXPERIENCE AND ACTIVITIES

2016-2018 **Director of the Data Coordination Center, Rome Foundation Global Study of the Epidemiology of Functional GI Disorders.** In charge of collecting all electronic survey data from more than seventy thousand individuals in the general population in 33 countries.

2015-2016 **Co-Chair, 2016 Scientific Program of the Annual Meeting of the American Society for Clinical Hypnosis, St. Louis, Missouri**

2014-2016 **Co-chair, Rome IV Diagnostic Questionnaire Development Committee**

2002-present **Design, programming and implementation of secure Internet-based symptom-tracking and therapeutic web applications.**

2005-present **Advisory Editor, *American Journal of Clinical Hypnosis***

2005-present **Associate Editor, *Applied Psychophysiology and Biofeedback***

2002-present **Reviewer for the following journals:**

Gastroenterology
American Journal of Gastroenterology
Lancet Gastroenterology and Hepatology
Psychosomatic Medicine
American Journal of Clinical Hypnosis
Neurogastroenterology and Motility
Applied Psychophysiology and Biofeedback
Journal of Psychosomatic Research
International Journal of Clinical and Experimental Hypnosis
Alimentary Pharmacology & Therapeutics
Journal of Clinical Psychology in Medical Settings
Evidence-based Complementary and Alternative Medicine

2006-2011 **Advisory Editor, *Biofeedback Newsmagazine***

2009 **Provided expert testimony and presented research data at a U.S. Food and Drug Administration pre-IND trial design meeting.**

2008-2009 **Consultant on research trial design for two pharmaceutical companies**

2004-2009 **Director, D.A.T.A. Core, UNC Center for Functional G.I. and Motility Disorders. A position with half-time funding provided by an NIH infrastructure grant.** Designed data collection methodologies and supervised data collection and data processing in more than 40 research studies, using methods such as secure internet-mediated clinical symptom assessment and longitudinal symptom status tracking, high-speed questionnaire scanning, and large mail surveys. Provided data analysis services and consultation on design of data collection projects to UNC investigators and outside collaborators.

2005-2006 **Member, Rome III Diagnostic Criteria Validation Working Team**

2005 **Guest Editor, *International Journal of Clinical and Experimental Hypnosis*, Special Issue on IBS and Hypnosis.**

2003-2004 **Chair, Review Committee, AAPB Efficacy Review of Biofeedback for Functional Anorectal Disorders**

- 2004 **Course Director. *Hypnosis Treatment for Functional Gastrointestinal Disorders: A Training Course for Health Professionals. A 3½ Day Course, Research Triangle Park, NC.***
- 2003-2004 **Chair, Committee for Research and Science, American Society for Clinical Hypnosis**
- 2002-2004 **Associate Editor, *American Journal of Clinical Hypnosis***
- 2002 **Member, Research and Science Task Force, American Society for Clinical Hypnosis**
- 2001-2002 **Member, Doctoral Dissertation Committee for Stephanie T. Nevin, Psy.D. Eastern Virginia Medical School.**
- 1998-2000 **Consultant, NIDDK funded five-year research project in the pathophysiology of irritable bowel syndrome, UNC-Chapel Hill. Principal Investigator: William E. Whitehead, Ph.D.**
- 1998-2000 **Member, Institutional Review Board, Eastern Virginia Medical School**
- 1998-2000 **Clinical supervisor, behavioral medicine training rotation for doctoral students in clinical psychology, Eastern Virginia Medical School**
- 1998-2001 **Chair, Electronic Communications Committee. Association for Applied Psychophysiology and Biofeedback.**
- 1998-2000 **Board Member, Primary Care Section, Association for Applied Psychophysiology and Biofeedback.**
- 1998-2000 **Member, Education Committee, Association for Applied Psychophysiology and Biofeedback.**
- 1997-1999 **Member, Program Committee, Association for Applied Psychophysiology and Biofeedback. 30th AAPB Annual Meeting, Vancouver, Canada, April 1999.**
- 1996-1997 **Co-Chair, Membership Committee, American Psychological Association Division 30.**
- Nov. 1996 **Completed the 9-day 80-hour *Professional Biofeedback Certification Training Course.* Stens Corporation. Orlando, Florida.**
- Nov. 1996 **Completed a 20 hour training course in EEG Biofeedback, Stens Corporation. Orlando, Florida.**
- 1995-1996 **Program Co-Chair, American Psychological Association Division 30. Co-chair of the APA Psychological Hypnosis division program for the 104th Annual Meeting in Toronto, Canada in August 1996.**
- Jan. 1994-
May 1994 **Adjunct Psychology Instructor. Methodist College, Fayetteville, North Carolina. Taught a 300-level undergraduate course in Human Lifespan Development.**
- Aug. 1989-
May 1991 **Clinical Trainee and Research Assistant. Behavioral Medicine Clinic and Stress Disorders Laboratory Eastern Virginia Medical School. Norfolk, Virginia.**

Aug. 1988- **Instructor in Psychology.** Egilsstadir College, Egilsstadir, Iceland.
 May 1989 Taught undergraduate psychology courses: *Statistics, Introductory psychology, Abnormal psychology, Psychological development, Personality.*

PUBLICATIONS

A. BOOK CHAPTERS

1. **Palsson O.S.** Psychological Treatments of GI Diseases. In Encyclopedia of Gastroenterology, 2nd Edition. Elsevier. (In press).
2. **Palsson O.S.** Hypnotic treatment of chronic gastrointestinal pain. In Jensen M. ed. Hypnosis for Chronic Pain: Favorite Strategies of Master Clinicians. Denny Creek Press, Seattle, WA. (In press)
3. **Palsson O.S.** (2016). Irritable Bowel Syndrome. Chapter 29. In Elkins, G (Ed.) *Handbook of Medical and Psychological Hypnosis: Foundations, Applications and Professional Issues*, pp. 283-293. NY: Spring Publishing.
4. Whitehead, W.E., **Palsson, O.S.** (2013). Behavioral treatment of fecal incontinence. Chapter 37. In: D.I. Mostofsky (Ed.), *Handbook in Behavioral Medicine*, pp. 787-806. New York, Wiley-Blackwell.
5. Van Tilburg M.A.L., Weinland S.R., **Palsson O.S.** (2011). Brief Review of Mind-Body Medicine in Gastroenterology Practice. In: G Mullin (Ed). *Integrative Gastroenterology*, pp 326-336. New York, NY: Oxford University Press.
6. **Palsson, O.S.** & Blanco, H.E. (2009). Hipnoterapia en trastornos funcionales gastrointestinales. In: Blanco HE, Rodriguez, JT & Schneider, RE (Eds), pp. 753-763. *Síndrome de Intestino Irritable y otros Trastornos Relacionados*. Mexico City: Editorial Medica Panamerica.
7. Whitehead W.E. & **Palsson O.S.** (2007). Hyperalgesia in irritable bowel syndrome: cognitive and physiological influences on pain perception. In: Howden, C.W. *Advances in Digestive Disease*, pp. 37-48. Bethesda, MD: AGA Institute Press.
8. **Palsson, O.S.** & Moss, D. (2007). Irritable Bowel Syndrome (IBS) Concurrent with Fibromyalgia (Chapter 9). In S. Ostalecky (Ed.) *Fibromyalgia: The complete guide from medical experts and patients*, pp 119-127. Sudbury, Massachusetts: Jones & Bartlett.
9. Whitehead, W.E., Thompson, W.G., **Palsson, O.S.**, Thiwan, S., Talley, N., Chey, W., Irvine, E.J., Drossman, D.A., & Walker, L. (2006). Development and validation of the Rome III Diagnostic Questionnaire (Chapter 16). In: Drossman DA, Corazziari, Delvaux M, Spiller R, Talley NJ, Thompson WG, and Whitehead WE (Eds), *Rome III: The Functional Gastrointestinal Disorders*, pp 835-853. McLean, Virginia: Degnon Associates.
10. Pope, A.T. & **Palsson, O.** (2003). Converging Technologies for Physiological Self-regulation. In Roco, M.C. and Bainbridge, W.S. (eds.) *Converging Technologies for Improving Human Performance: Nanotechnology, Biotechnology, Information Technology and Cognitive Science*, pp 260- 270. Dordrecht, The Netherlands: Kluwer Academic Publishers.
11. **Palsson, O.S.** & Collins, R. (2002). Functional bowel and anorectal disorders. In Moss, D., Wickramasekera, I.E., Davies, T.C., McGrady A. (eds.) *Handbook of Mind-Body Medicine for Primary Care*, pp. 299-311. Thousand Oaks, CA: Plenum.

12. **Palsson, O.S.** (2002). Urinary incontinence. In Moss, D., Wickramasekera, I.E., Davies, T.C., McGrady A. (eds.) *Handbook of Mind-Body Medicine for Primary Care*, pp. 312-321. Thousand Oaks, CA: Plenum.
13. Davies, S. M. & **Palsson, O.S.** (2002). Medical education for mind-body medicine. *Handbook of Mind-Body Medicine for Primary Care*, 443-448. Thousand Oaks, CA: Plenum.

B. PAPERS PUBLISHED AND IN PRESS

1. **Palsson OS**, Twist S, Walker ME. A National Survey of Clinical Hypnosis Views and Experiences in the Adult Population in the United States. *International Journal of Clinical and Experimental Hypnosis* 2019 (In press).
2. **Palsson OS**. Is Hypnotherapy Helpful for Primary and Secondary Care IBS? *Lancet Gastroenterol Hepatol.* 2019 Jan;4(1):2-3..
3. **Palsson OS**. Development and validation of the Thought Impact Scale: A measure of subconscious connectedness. *American Journal of Clinical Hypnosis* 2019 (in press).
4. Simrén M, Törnblom H, **Palsson OS**, Van Oudenhove L, Whitehead WE, Tack J. Cumulative Effects of Psychologic Distress, Visceral Hypersensitivity, and Abnormal Transit on Patient-reported Outcomes in Irritable Bowel Syndrome. *Gastroenterology.* 2019 Apr 22.
5. Meyer-Kalos PS, Ludwig KA, Gaylord S, Perkins DO, Grewen K, **Palsson OS**, Burchinal M, Penn DL. Enhancing stress reactivity and wellbeing in early schizophrenia: A pilot study of individual coping awareness therapy (I-CAT). *Schizophr Res.* 2018 Nov;201:413-414. PubMed PMID: 29735201.
6. Clevers E, Whitehead WE, **Palsson OS**, Sperber AD, Törnblom H, Van Oudenhove L, Tack J, Simrén M. Reply. *Clin Gastroenterol Hepatol.* 2018 Oct 10. pii: S1542-3565(18)31092-9. PubMed PMID: 30315945.
7. Polster AV, **Palsson OS**, Törnblom H, Öhman L, Sperber AD, Whitehead WE, Simrén M. Population-based IBS subgroups characterized by specific profiles of GI and non-GI symptoms identified through Mixture Model analysis report differences in healthcare utilization. *Neurogastroenterol Motil.* 2019 Jan;31(1):e13483. doi: 10.1111/nmo.13483. Epub 2018 Nov 4. PMID: 30393924.
8. Josefsson A, **Palsson OS**, Simrén M, Sperber AD, Törnblom H, Whitehead WE. Oesophageal symptoms are common and associated with other functional gastrointestinal disorders (FGIDs) in an English-speaking Western population. *United European Gastroenterol J.* 2018 Dec;6(10):1461-1469.
9. Clevers E, Whitehead WE, Palsson OS, Sperber AD, Törnblom H, Van Oudenhove L, Tack J, Simrén M. Factor Analysis Defines Distinct Upper and Lower Gastrointestinal Symptom Groups Compatible With Rome IV Criteria in a Population-based Study. *Clin Gastroenterol Hepatol.* 2018 Aug;16(8):1252-1259.e5. PubMed PMID: 29510215.
10. Tanaka Y, Kanazawa M, **Palsson OS**, Tilburg MAV, Gangarosa LM, Fukudo S, Drossman DA, Whitehead WE. Increased Postprandial Colonic Motility and Autonomic Nervous System Activity in Patients With Irritable Bowel Syndrome: A Prospective Study. *J Neurogastroenterol Motil.* 2018

Jan 30;24(1):87-95. doi: 10.5056/jnm16216. PubMed PMID: 29291610; PubMed Central PMCID: PMC5753907.

11. Robin SG, Keller C, Zwiener R, Hyman PE, Nurko S, Saps M, Di Lorenzo C, Shulman RJ, Hyams JS, **Palsson O**, van Tilburg MAL. Prevalence of Pediatric Functional Gastrointestinal Disorders Utilizing the Rome IV Criteria. *J Pediatr.* 2018 Feb 2. pii: S0022-3476(17)31634-7. doi: 10.1016/j.jpeds.2017.12.012. [Epub ahead of print] PubMed PMID: 29398057.
12. Mann DJ, Faurot KR, MacIntosh B, **Palsson OS**, Suchindran CM, Gaylord SA, Lynch C, Johnston A, Maiden K, Barrow DA, Hibbeln JR, Ramsden CE. A sixteen-week three-armed, randomized, controlled trial investigating clinical and biochemical effects of targeted alterations in dietary linoleic acid and n-3 EPA+DHA in adults with episodic migraine: study protocol. *Prostaglandins Leukot Essent Fatty Acids.* 2018 Jan;128:41-52. PubMed PMID: 29413360.
13. Keefer L, **Palsson OS**, Pandolfino JE. Best Practice Update: Incorporating psychogastroenterology into the routine management of digestive disorders. *Gastroenterology* 2018 Jan 31. pii: S0016-5085(18)30113-6. doi: 10.1053/j.gastro.2018.01.045. [Epub ahead of print] Review. PubMed PMID: 29410117.
14. Bedard K, Heymen S, **Palsson OS**, Bharucha AE, Whitehead WE. Relationship between symptoms and quality of life in fecal incontinence. *Neurogastroenterol Motil.* 2017 Nov 2. doi: 10.1111/nmo.13241. [Epub ahead of print] PubMed PMID: 29094789.
15. Bennet, SMP, **Palsson OS**, Whitehead WE, Barrow DA, Hans Törnblom H, Lena Öhman L, Simrén M, van Tilburg MA. Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome (IBS) but largely unrelated to symptom characteristics. Submitted manuscript.
16. Aziz I, Törnblom H, **Palsson OS**, Whitehead WE, Simrén M. How the change in IBS criteria from Rome III to Rome IV impacts on clinical characteristics and key pathophysiological factors. Submitted manuscript.
17. Aziz I, **Palsson OS**, Törnblom H, Sperber AD, Whitehead WE, Simrén M. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. *Lancet Gastroenterol Hepatol.* 2018 Jan 29. pii: S2468-1253(18)30003-7. PubMed PMID: 29396034.
18. Aziz I, **Palsson OS**, Törnblom H, Sperber AD, Whitehead WE, Simrén M. The Prevalence and Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries. *Am J Gastroenterol.* 2018 Jan;113(1):86-96. PubMed PMID: 29134969.
19. Simrén M, Törnblom H, **Palsson OS**, Whitehead WE. Management of the multiple symptoms of irritable bowel syndrome. *Lancet Gastroenterol Hepatol.* 2017 Feb;2(2):112-122. Review. PubMed PMID: 28403981.
20. Simren M, **Palsson OS**, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. *Curr Gastroenterol Rep.* 2017 Apr;19(4):15. Review. PubMed PMID: 28374308; PubMed Central PMCID: PMC5378729.
21. Whitehead WE, **Palsson OS**, Simrén M. Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? *Expert Rev Gastroenterol Hepatol.* 2017 Apr;11(4):281-283. PubMed PMID: 28276814.
22. Heymen S, **Palsson O**, Simren M, Whitehead WE. Patient preferences for endpoints

in fecal incontinence treatment studies. *Neurogastroenterol Motil.* 2017 May;29(5). PubMed PMID: 28271624.

23. Simrén M, Törnblom H, **Palsson OS**, van Tilburg MA, Van Oudenhove L, Tack J, Whitehead WE. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. *Gut.* 2017 Jan 19. PubMed PMID: 28104632.
24. Simrén M, **Palsson OS**, Heymen S, Bajor A, Törnblom H, Whitehead WE. Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients. *Neurogastroenterol Motil.* 2017 Feb;29(2). PubMed PMID: 27581702; PubMed Central PMCID: PMC5276715.
25. Whitehead WE, **Palsson OS**, Simrén M. Biomarkers to distinguish functional constipation from irritable bowel syndrome with constipation. *Neurogastroenterol Motil.* 2016 Jun;28(6):783-92. Review. PubMed PMID: 27214096.
26. **Palsson OS**. A specific link between migraine and functional GI disorders. *The Lancet Gastroenterology & Hepatology* 2016, 1(2):89-90.
27. Lewis ML, **Palsson OS**, Whitehead WE, van Tilburg MA. Prevalence of Functional Gastrointestinal Disorders in Children and Adolescents. *J Pediatr.* 2016 May 4. pii: S0022-3476(16)30056-7. PubMed PMID: 27156185.
28. Whitehead WE, **Palsson OS**, Simren M. Treating Fecal Incontinence: An Unmet Need in Primary Care Medicine. *N C Med J.* 2016 May-Jun;77(3):211-5. doi: 10.18043/ncm.77.3.211. PubMed PMID: 27154893.
29. **Palsson OS**, Whitehead WE, van Tilburg MA, Chang L, Chey W, Crowell MD, Keefer L, Lembo AJ, Parkman HP, Rao SS, Sperber A, Spiegel B, Tack J, Vanner S, Walker LS, Whorwell P, Yang Y. Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. *Gastroenterology* 2016; 150(6):1481–1491. PubMed PMID: 27144634.
30. Kanazawa M, Nakajima S, Oshima T, Whitehead WE, Sperber AD, **Palsson OS**, Drossman DA, Miwa H, Fukudo S. Validity and Reliability of the Japanese Version of the Rome III Diagnostic Questionnaire for Irritable Bowel Syndrome and Functional Dyspepsia. *J Neurogastroenterol Motil.* 2015 Oct 1;21(4):537-44. doi: 10.5056/jnm15016. PubMed PMID: 26350938; PubMed Central PMCID: PMC4622136.
31. **Palsson OS**. Hypnosis Treatment of Gastrointestinal Disorders: A Comprehensive Review of the Empirical Evidence. *Am J Clin Hypn.* 2015 Oct;58(2):134-58.
32. **Palsson OS**, van Tilburg M. Hypnosis and Guided Imagery Treatment for Gastrointestinal Disorders: Experience With Scripted Protocols Developed at the University of North Carolina. *Am J Clin Hypn.* 2015;58(1):5-21. doi: 10.1080/00029157.2015.1012705. PubMed PMID: 26046714.
33. Kiken LG, Garland EL, Bluth K, **Palsson OS**, Gaylord SA. From a state to a trait: Trajectories of state mindfulness in meditation during intervention predict changes in trait mindfulness. *Pers Individ Dif.* 2015 Jul 1;81:41-46. PubMed PMID: 25914434; PubMed Central PMCID: PMC4404745.
34. Riehl ME, Pandolfino JE, **Palsson OS**, Keefer L. Feasibility and acceptability of esophageal-directed hypnotherapy for functional heartburn. *Dis Esophagus.* 2015 Mar 30. doi: 10.1111/dote.12353. [Epub ahead of print] PubMed PMID: 25824436.

35. Ramsden CE, Faurot KR, Zamora D, **Palsson OS**, MacIntosh BA, Gaylord S, Taha AY, Rapoport SI, Hibbeln JR, Davis JM, Mann JD. Targeted alterations in dietary n-3 and n-6 fatty acids improve life functioning and reduce psychological distress among patients with chronic headache: a secondary analysis of a randomized trial. *Pain*. 2015 Apr;156(4):587-96. doi: 10.1097/01.j.pain.0000460348.84965.47. PubMed PMID: 25790451.
36. van Tilburg MA, Hyman PE, Walker L, Rouster A, **Palsson OS**, Kim SM, Whitehead WE. Prevalence of Functional Gastrointestinal Disorders in Infants and Toddlers. *J Pediatr*. 2014 Dec 31. pii: S0022-3476(14)01114-7. doi: 10.1016/j.jpeds.2014.11.039. [Epub ahead of print] PubMed PMID: 25557967.
37. Dorn SD, **Palsson OS**, Woldeghebriel M, Fowler B, McCoy R, Weinberger M, Drossman DA. Development and pilot testing of an integrated, web-based self-management program for irritable bowel syndrome (IBS). *Neurogastroenterol Motil*. 2015 Jan;27(1):128-34. doi: 10.1111/nmo.12487. Epub 2014 Dec 6. PubMed PMID: 25482042.
38. **Palsson OS**, Baggish J, Whitehead WE. Episodic nature of symptoms in irritable bowel syndrome. *Am J Gastroenterol*. 2014 Sep;109(9):1450-60. doi: 10.1038/ajg.2014.181. Epub 2014 Jul 1. PubMed PMID: 24980882.
39. Ringel-Kulka T, Goldsmith JR, Carroll IM, Barros SP, **Palsson O**, Jobin C, Ringel Y. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study. *Aliment Pharmacol Ther*. 2014 Jul;40(2):200-7. doi: 10.1111/apt.12800. Epub 2014 May 22. PubMed PMID: 24853043.
40. Kanazawa M, **Palsson OS**, van Tilburg MA, Gangarosa LM, Fukudo S, Whitehead WE. Motility response to colonic distention is increased in postinfectious irritable bowel syndrome (PI-IBS). *Neurogastroenterol Motil*. 2014 May;26(5):696-704. doi: 10.1111/nmo.12318. Epub 2014 Feb 13. PubMed PMID: 24602083.
41. van Tilburg MA, **Palsson OS**, Ringel Y, Whitehead WE. Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. *Complement Ther Med*. 2014 Feb;22(1):17-20. PubMed PMID: 24559811; PubMed Central PMCID: PMC3958926.
42. Chiarioni G, **Palsson OS**, Asteria CR, Whitehead WE. Neuromodulation for fecal incontinence: an effective surgical intervention. *World J Gastroenterol*. 2013 Nov 7;19(41):7048-54. PubMed PMID: 24222947; PubMed Central PMCID: PMC3819539.
43. Keefer L, Taft TH, Kiebles JL, Martinovich Z, Barrett TA, **Palsson OS**. Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. *Aliment Pharmacol Ther*. 2013 Oct;38(7):761-71. PubMed PMID: 23957526.
44. Ramsden CE, Faurot KR, Zamora D, Suchindran CM, Macintosh BA, Gaylord S, Ringel A, Hibbeln JR, Feldstein AE, Mori TA, Barden A, Lynch C, Coble R, Mas E, **Palsson O**, Barrow DA, Douglas Mann J. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial. *Pain*. 2013 Jul 22. PubMed PMID: 23886520.
45. van Tilburg MA, **Palsson OS**, Whitehead WE. Which psychological factors exacerbate irritable bowel syndrome? Development of a comprehensive model. *J Psychosom Res*. 2013 Jun;74(6):486-92. PubMed PMID: 23731745; PubMed Central PMCID: PMC3673027.
46. Markland AD, **Palsson O**, Goode PS, Burgio KL, Busby-Whitehead J, Whitehead WE.

Association of low dietary intake of fiber and liquids with constipation: evidence from the National Health and Nutrition Examination Survey. *Am J Gastroenterol.* 2013 May;108(5):796-803. PubMed PMID: 23567352.

47. **Palsson OS**, Whitehead WE. Psychological treatments in functional gastrointestinal disorders: a primer for the gastroenterologist. *Clin Gastroenterol Hepatol.* 2013 Mar;11(3):208-16. PubMed PMID: 23103907; PubMed Central PMCID: PMC3591464.
48. Robinson BL, Matthews CA, **Palsson OS**, Geller E, Turner M, Parnell B, Crane A, Jannelli M, Wells E, Connolly A, Lin FC, Whitehead WE. Obstetric sphincter injury interacts with diarrhea and urgency to increase the risk of fecal incontinence in women with irritable bowel syndrome. *Female Pelvic Med Reconstr Surg.* 2013 Jan-Feb;19(1):40-5. PubMed PMID: 23321658.
49. MacLean EW, **Palsson OS**, Turner MJ, Whitehead WE. Development and validation of new disease-specific measures of somatization and comorbidity in IBS. *J Psychosom Res.* 2012 Nov;73(5):351-5. PubMed PMID: 23062808.
50. Gaylord SA, **Palsson OS**, Garland EL, Furot KR, Mann JD, Whitehead WE. Reply to "A Mindful Way Through IBS: Reducing Abdominal Pain And Improving Quality Of Life". *Gastroenterology* 2012 May;142(5): 1450.
51. **Palsson OS**, Baggish JS, Turner MJ, Whitehead WE. IBS Patients Show Frequent Fluctuations Between Loose/Watery and Hard/Lumpy Stools: Implications for Treatment. *Am J Gastroenterol.* 2012 Feb;107(2):286-95
52. Boregowda SC, Choate RE, Handy R, **Palsson OS**. Thermodynamic Assessment of Multiple Physiological Stress Responses Using Maxwell Relations. *International Journal of Modern Engineering Research*, Vol.2, Issue.2, Mar-Apr 2012, 297-302.
53. Garland EL, Gaylord SA, **Palsson O**, Furot K, Mann JD, Whitehead WE. Therapeutic mechanisms of a mindfulness-based treatment for IBS: Effects on visceral sensitivity, catastrophizing, and affective processing of pain sensations. *J Behav Med.* 2011 Dec 8. [Epub ahead of print] PMID:22161025.
54. Whitehead WE, **Palsson OS**, Gangarosa L, Turner M, Tucker J. Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. *Neurogastroenterol Motil.* 2011 Oct;23(10):944-e400 PMID: 21914041.
55. Gaylord SA, **Palsson OS**, Garland EL, Furot KR, Coble RS, Mann JD, Frey W, Leniek K, Whitehead WE. Mindfulness Training Reduces the Severity of Irritable Bowel Syndrome in Women: Results of a Randomized Controlled Trial. *Am J Gastroenterol.* 2011 Sep;106(9):1678-88. PMID: 21914041.
56. Whitehead WE, **Palsson OS**, Gangarosa L, Turner M, Tucker J. Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. *Neurogastroenterol Motil.* 2011 Oct;23(10):944-950. PMID: 21914041.
57. Nyrop KA, Grover M, **Palsson OS**, Heymen S, Palmer MH, Goode PS, Whitehead WE, Busby-Whitehead J. Likelihood of nursing home referral for fecally incontinent elderly patients is influenced by physician views on nursing home care and outpatient management of fecal incontinence. *J Am Med Dir Assoc.* 2012 May;13(4):350-4. PubMed PMID: 21450249.
58. Ringel-Kulka T, **Palsson OS**, Maier D, Carroll I, Galanko JA, Leyer G, Ringel Y. Probiotic Bacteria *Lactobacillus acidophilus* NCFM and *Bifidobacterium lactis* Bi-07 Versus Placebo for the Symptoms of Bloating in Patients With Functional Bowel Disorders: A Double-blind Study. *J Clin Gastroenterol.* 2011 Jul;45(6):518-25.

59. Shinozaki M, Kanazawa M, **Palsson OS**, Sagami Y, Endo Y, Hongo M, Drossman DA, Whitehead WE, Fukudo S. Validation of the Japanese version of comorbid conditions questionnaire (CCQ-J) and recent physical symptoms questionnaire (RPSQ-J). *Intern Med.* 2011;50(5):375-80.
60. Keefer L, Kiebles JL, Kwiatek MA, **Palsson O**, Taft TH, Martinovich Z, Barrett TA. The potential role of a self-management intervention for ulcerative colitis: a brief report from the ulcerative colitis hypnotherapy trial. *Biol Res Nurs.* 2012 Jan;14(1):71-7. PubMed PMID: 21362636.
61. **Palsson OS**. Hypnosis Treatment for Gut Problems. *European Gastroenterology & Hepatology Review*, 2010;6(1):42–6.
62. **Palsson OS**. Getting to the heart of cognitive-behavioral therapy effects on non-cardiac chest pain. *J Psychosom Res.* 2010 Sep;69(3):237-9.
63. Wong RK, **Palsson OS**, Turner MJ, Levy RL, Feld AD, von Korff M, Whitehead WE. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. *Am J Gastroenterol.* 2010 Oct;105(10):2228-34. PubMed PMID: 20502449.
64. Dunivan GC, Heymen S, **Palsson OS**, von Korff M, Turner MJ, Melville JL, Whitehead WE. Fecal incontinence in primary care: prevalence, diagnosis, and health care utilization. *Am J Obstet Gynecol.* 2010 May;202(5):493.e1-6.
65. Grover M, Busby-Whitehead J, Palmer MH, Heymen S, **Palsson OS**, Goode PS, Turner M, Whitehead WE. Survey of geriatricians on the impact of fecal incontinence on nursing home referral. *Journal of the American Geriatrics Society* 2010 May 7. [Epub ahead of print] PubMed PMID: 20487073
66. Gaylord SA, Whitehead WE, Coble RS, Faurot KR, **Palsson OS**, Garland EL, Frey W, Mann JD. Mindfulness for irritable bowel syndrome: protocol development for a controlled clinical trial. *BMC Complement Altern Med.* 2009 Jul 28;9:24.
67. Halpert A, Dalton CB, Palsson O, Morris C, Hu Y, Bangdiwala S, Hankins J, Norton N, Drossman DA. Irritable bowel syndrome patients' ideal expectations and recent experiences with healthcare providers: a national survey. *Dig Dis Sci.* 2010 Feb;55(2):375-83. PubMed PMID: 19513835.
68. Jones MP, Keefer L, Bratten J, Taft TH, Crowell MD, Levy R, **Palsson O**. Development and initial validation of a measure of perceived stigma in irritable bowel syndrome. *Psychol Health Med.* 2009 May;14(3):367-74.
69. Van Tilburg MA, Chitkara DK, **Palsson OS**, Levy RL, Whitehead WE. Parental worries and beliefs about abdominal pain. *J Pediatr Gastroenterol Nutr.* 2009 Mar;48(3):311-7.
70. Charioni G, **Palsson OS**, Whitehead WE. Hypnosis and upper digestive function and disease. *World J Gastroenterol* 2008 November 7; 14(41): 6276-6284
71. Kanazawa M, **Palsson OS**, Thiwan SI, Turner MJ, van Tilburg MA, Gangarosa LM, Chitkara DK, Fukudo S, Drossman DA, Whitehead WE. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. *Am J Gastroenterol.* 2008 Oct;103(10):2550-61.
72. Van Tilburg MA, **Palsson OS**, Levy RL, Feld AD, Turner MJ, Drossman DA, Whitehead WE. Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. *BMC Complement Altern Med.* 2008 Jul 24;8:46.

73. Grover M, Kanazawa M, **Palsson OS**, Chitkara DK, Gangarosa LM, Drossman DA, Whitehead WE. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. *Neurogastroenterol Motil.* 2008 Sep;20(9):998-1008.
74. Halpert A, Dalton CB, **Palsson O**, Morris C, Hu Y, Bangdiwala S, Hankins J, Norton N, Drossman DA. Patient Educational Media Preferences for Information About Irritable Bowel Syndrome (IBS). *Dig Dis Sci.* 2008 Dec;53(12):3184-90.
75. Whitehead WE, **Palsson OS**, Levy RR, Feld AD, Turner M, Von Korff M. Comorbidity in irritable bowel syndrome. *Am J Gastroenterol.* 2007 Dec;102(12):2767-76.
76. Dorn SD, **Palsson OS**, Thiwan SIM, Kanazawa M, Clark WC, Van Tilburg MAL, Drossman DA, Scarlett Y, Levy RL, Ringel Y, Crowell MD, Olden KW, Whitehead WE. Colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. *Gut* 2007; 56:1202-1209.
77. Nyrop KA, **Palsson OS**, Levy RL, Von Korff M, Feld AD, Turner MJ, Whitehead WE. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhea and functional abdominal pain. *Aliment Pharmacol Ther.* 2007;26:237-48.
78. Halpert A, Dalton CB, **Palsson O**, Morris C, Hu Y, Bangdiwala S, Hankins J, Norton N, Drossman D. What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educational Needs Questionnaire (PEQ). *Am J Gastroenterol.* 2007 Sep;102(9):1972-82. PubMed PMID: 17488254.
79. Kanazawa M, Drossman DA, Shinozaki M, Sagami Y, Endo Y, **Palsson OS**, Hongo M, Whitehead WE, Fukudo S. Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). *Biopsychosoc Med.* 2007 Mar 3;1:6. PubMed PMID: 17371576
80. Whitehead WE, **Palsson OS.**, Levy, R.L., Feld, A.D., Von Korff, M., Turner M. (2006). Response to Dr. Allen Mangel's Letter. *American Journal of Gastroenterology*, 101(12):2885-6.
81. **Palsson OS**, Whitehead WE. Hypnosis for non-cardiac chest pain. *Gut* 2006, 55(10):1381-4.
82. **Palsson OS**. Should we incorporate psychological care into the management of IBS? *Nature Clinical Practice Gastroenterology & Hepatology* 2006, 3(9):474-5.
83. Whitehead WE, **Palsson OS**, Feld AD, Levy RL, Von Korff M, Turner MJ, Drossman DA. Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. *Aliment Pharmacol Ther.* 2006 Jul 1;24(1):137-46. PubMed PMID: 16803612
84. **Palsson OS**, Heymen S. Treatment of functional anorectal disorders: Biofeedback is proving its value like never before. *Biofeedback* 2006, 34(1), 20-24.
85. Whitehead WE, **Palsson OS**, Levy RL, Feld AD, VonKorff M, Turner M. Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. *Am J Gastroenterol.* 2006 May;101(5):1057-65. PubMed PMID: 16573774.
86. **Palsson OS**, Turner MJ, Whitehead WE. Hypnosis home treatment for irritable bowel syndrome: a pilot study. *Int J Clin Exp Hypn.* 2006 Jan;54(1):85-99. PubMed PMID: 16316885.

87. **Palsson OS**. Standardized hypnosis treatment for irritable bowel syndrome: the North Carolina protocol. *Int J Clin Exp Hypn*. 2006 Jan;54(1):51-64. PubMed PMID: 16316883.
88. **Palsson OS**. Editor's preamble: the nature of IBS and the need for a psychological approach. *Int J Clin Exp Hypn*. 2006 Jan;54(1):1-6. PubMed PMID:16316879.
89. **Palsson OS**. Hypnosis treatment of irritable bowel syndrome: Effects on symptoms and psychophysiology. *Biofeedback*, Spring 2005: 20-25.
90. **Palsson OS**, Drossman DA. Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. *Gastroenterology Clinics of North America* 2005, 34(2):281-303.
91. **Palsson OS**, Whitehead WE. Comorbidity Associated With Irritable Bowel Syndrome. *Psychiatric Annals* 2005, 35(4), 320-329.
92. Palsson, O.S., Morteau, O., Bozyski, E.M., Woosley, J.T., Sartor, R.B., & Whitehead, W.E. (2004). Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. *Digestive Diseases and Sciences*, 49 (7-8): 1236-1243
93. **Palsson OS**, Heymen S, Whitehead WE. Biofeedback treatment for functional anorectal disorders: A comprehensive efficacy review. *Applied Psychophysiology and Biofeedback* 2004, 29(3):153-174.
94. **Palsson OS**. Psychological treatments for functional gastrointestinal disorders: Current status. *Functional Brain-Gut Newsletter* 2004, 32: 16-38.
95. Moss D, Sella GE, Andrasik F, Donaldson S, Lehrer P, **Palsson O**, Peper E, Sterman MB. Current applications of biofeedback to physical medicine and rehabilitation. *Europa Medicophysica* 2003, 39, 165-170.
96. Whitehead WE, Levy RL, Von Korff M, Feld AD, **Palsson OS**, Turner M, Drossman DA. The usual medical care for irritable bowel syndrome. *Aliment Pharmacol Ther*. 2004 Dec;20(11-12):1305-15. PubMed PMID: 15606392.
97. Rabiner DL, **Palsson OS**, Freer P. Does neurofeedback help kids with AD/HD? *Attention! Magazine* 2003: 30-35.
98. Whitehead WE, Bassotti G, **Palsson O**, Taub E, Cook EC 3rd, Drossman DA. Factor analysis of bowel symptoms in US and Italian populations. *Dig Liver Dis*. 2003, Nov;35(11):774-83. PubMed PMID: 14674667.
99. **Palsson OS**. Review of "The Psychopathology of Functional Somatic Syndromes". *Functional Brain-Gut Newsletter* 2005, 34: 8.
100. **Palsson OS**. Results of a national survey of the effects of changes in female sex hormones on irritable bowel syndrome. *Digest, Newsletter of the UNC Center for Functional GI and Motility Disorders*, Summer 2003:1-6.
101. **Palsson OS**, Whitehead WE. The growing case for hypnosis as adjunctive therapy for functional gastrointestinal disorders. *Gastroenterology*. 2002 Dec;123(6):2132-5. Review. PubMed PMID: 12454867.

102. **Palsson OS**, Turner MJ, Johnson DA, Burnett CK, Whitehead WE. Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. *Dig Dis Sci*. 2002 Nov;47(11):2605-14. PubMed PMID: 12452403.
103. **Palsson OS**, Pope AT. Morphing beyond recognition: The future of biofeedback technologies. *Biofeedback 2002*, 14(30), 14-18.
104. Whitehead WE, **Palsson O**, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? *Gastroenterology*. 2002 Apr;122(4):1140-56. Review. PubMed PMID:11910364.
105. **Palsson OS**. Hypnosis treatment of irritable bowel syndrome. *Participate*, Newsletter of the International Foundation for Functional Gastrointestinal Disorders, 2002, 11(3):4-6.
106. **Palsson OS**, Whitehead WE. IBS beyond the bowel: The meaning of co-existing disorders. *Digest, Newsletter of the UNC Center for Functional GI and Motility Disorders, Spring 2002: 8-11*.
107. **Palsson OS**. Irritable bowel syndrome and quality of life. *Digest, Newsletter of the UNC Center for Functional GI and Motility Disorders, Fall 2002: 8-11*.
108. Gibbs-Gallagher N, **Palsson OS**, Levy RL, Meyer K, Drossman DA, Whitehead WE. Selective recall of gastrointestinal-sensation words: evidence for a cognitive-behavioral contribution to irritable bowel syndrome. *Am J Gastroenterol*. 2001 Apr;96(4):1133-8. PubMed PMID: 11318007.
109. **Palsson OS**. The effects of hypnosis on the gastrointestinal tract. *Digest, Newsletter of the UNC Center for Functional GI and Motility Disorders 2001*, 6(1), 1-13.
110. **Palsson OS**, Whitehead WE. Hormones and irritable bowel syndrome. *Digest, Newsletter of the UNC Center for Functional GI and Motility Disorders, Spring 2002: 1-8*.
111. **Palsson OS**. Altered visceral perception in irritable bowel syndrome. *Practical Gastroenterology 1999*, 23(3): 52-63.
112. **Palsson OS**. The role of visceral hypersensitivity in IBS has not been established: A response to Dr. Quigley's article. *Practical Gastroenterology 1999*, 23(3): 51.
113. **Palsson OS**, Davies SM. Building mind-body bridges in medical school: A model. *Biofeedback 1999*, 27(1): 21-23.
114. **Palsson OS**, Davies TC. Behavioral health services providers in primary care: Innovative models of health care and service delivery. *Biofeedback 1999*, 27(1),14-20.
115. Boregowda, SC, Tiwari SN., **Palsson OS**, Downing BK. Measuring the effects of information processing on psychophysiological stress responses. Proceedings of the 37th AIAA Aerospace Sciences Meeting, 1999. Reno, Nevada, AIAA paper no. 99-0980.
116. Whitehead WE, **Palsson OS**. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. *Gastroenterology*. 1998 Nov;115(5):1263-71. Review. PubMed PMID: 9797383.
117. Whitehead WE, Crowell MD, Davidoff AL, **Palsson OS**, Schuster MM. Pain from rectal distension in women with irritable bowel syndrome: relationship to sexual abuse. *Dig Dis Sci*. 1997 Apr;42(4):796-804. PubMed PMID: 9125652.

118. Boregowda SC, Tiwari SN, Chaturwedi SK., **Palsson OS**. An innovative approach to measuring and monitoring human stress levels in man/machine interactions. Proceedings of the 18th National Conference of the American Society of Engineering Management, 1997. Virginia Beach, VA: pp.5-13.
119. **Palsson OS**. Soothing the gut with hypnosis. Virginia Hypnosis Society Newsletter 1996, 5(1):5.
120. **Palsson OS**. The high risk model of threat perception as a framework for the development of treatments for psychophysiological disorders. Biofeedback, Spring 1996,24(1):14-17.
121. **Palsson OS**. The utilization of hypnosis in dentistry. Hardjagl, Journal of the Icelandic Dental Students Association 1994, 30:39-42.

C. PUBLISHED RESEARCH ABSTRACTS

1. Aziz I, **Palsson O**, Whitehead WE, Sperber AD, Simren M, Törnblom H. Epidemiology and Clinical Characteristics for Rome IV Functional Nausea and Vomiting Disorders in Adults. Gastroenterology 2018, Vol. 154, Issue 6, S-557.
2. Chiarioni G, **Palsson OS**, Heymen S, Cidoni F, Whitehead WE. Efficacy of Balloon Evacuation Test to Predict Biofeedback Outcomes for Constipation Due to Outlet Dysfunction. Gastroenterology, Vol. 154, Issue 6, S-542.
3. Aziz I, Törnblom H, **Palsson O**, Whitehead WE, Simren E. How the Change in IBS Criteria from Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Markers. Gastroenterology, Vol. 154, Issue 6, S-973.
4. Zwiener R, **Palsson OS**, Nurko S, Saps M, Di Lorenzo C, Shulman RJ, Hyams JS, Hyman PE, van Tilburg MA. Comparison of Clinician Diagnoses and Qpgs-Rome IV Questionnaire Diagnoses for Pediatric Functional Gastrointestinal Disorders in Children and Adolescents. Gastroenterology, Vol. 154, Issue 6, S-564.
5. **Palsson OS**, Heymen S, Busby-Whitehead J, Twist S, Whitehead WE. Six-Week Internet Self-Help Intervention Reduces Symptom Episodes by 50% or More in the Majority of Individuals with Fecal Incontinence: A Pilot Study. Gastroenterology, Vol. 154, Issue 6, S-184.
6. **Palsson OS**, Simren M, Higgins CS, Fox SM, Johnston JM, Bochenek W, Bartolini W, Tripp KJ, Whitehead WE. Reliability of, and Agreement Between, Rome III and Rome IV Irritable Bowel Syndrome (IBS) Subtyping by Means of Stool Diary. Gastroenterology, Vol. 154, Issue 6, S-977.
7. Aziz I, **Palsson OS**, Tornblom H, Sperber A, Whitehead WE. The prevalence of Rome IV functional dyspepsia and its impact on health impairment: Results from a three-country general population study. United European Gastroenterology Journal 2017, 5(5S): A65.
8. Clevers E, Whitehead WE, **Palsson OS**, Tornblom H, Van Oudenhove L, Tack J, Simren M. Factor analysis defines distinct upper and lower symptom groupings compatible with Rome IV in a population-based study. Clevers E, Whitehead WE, Palsson OS, Tornblom H, Van Oudenhove L, Simren M. United European Gastroenterology Journal 2017, 5(5S): A70.
9. Lövdahl J, **Palsson OS**, Ringstrom G, Törnblom H, Simren M. Individual versus group hypnotherapy for IBS: A randomized controlled trial. United European Gastroenterology Journal 2017, 5(5S): A120.

10. Aziz I, **Palsson OS**, Tornblom H, Sperber A, Whitehead WE, Simren M. The prevalence and impact of overlapping Rome IV functional gastrointestinal disorders on somatisation, quality of life, and health care utilisation: Results from a three-country general population study. *United European Gastroenterology Journal* 2017, 5(5S): A774.
11. Josefsson A, **Palsson OS**, Simren M, Sperber A, Tornblom H, Whitehead WE. Esophageal symptoms are common and related to other functional gastrointestinal disorders (FGIDs) in a Western population. *United European Gastroenterology Journal* 2017, 5(5S): A350.
12. Jossan N, Tornblom H, Simren M, Aziz I, Palsson OS, Whitehead WE, Sperber A. Health care utilization for Rome IV irritable bowel syndrome: A three-country survey in the general population. *United European Gastroenterology Journal* 2017, 5(5S): A775.
13. Jossan N, Tornblom H, Simren M, Aziz I, Palsson OS. What determines whether individuals with irritable bowel syndrome in the general population seek medical care for their disorder? *United European Gastroenterology Journal* 2017, 5(5S): A333.
14. Josefsson A, **Palsson OS**, Simren M, Sperber AD, Törnblom H, Whitehead WE. Esophageal Symptoms are Common and Related to other Functional Gastrointestinal Disorders (FGIDS) in a Western Population. *Gastroenterology* 2017, 152(5): S330.
15. Jossan N, Simren M, Sperber AD, Aziz I, Whitehead WE, **Palsson OS**, Törnblom H. What Determines Whether Individuals with Irritable Bowel Syndrome (IBS) in the General Population Seek Medical Care for their Disorder? *Gastroenterology* 2017, 152(5): S46.
16. Jossan N, Simren M, Sperber AD, Aziz I, Whitehead WE, Törnblom H, **Palsson OS**. Health Care Utilization for Rome IV Irritable Bowel Syndrome; A Three-Country Survey in the General Population. *Gastroenterology* 2017, 152(5), S68.
17. Bennet SM, **Palsson OS**, Whitehead WE, Barrow DA, Törnblom H, Ohman L, Simren M, van Tilburg MA. Serum Cytokines are Elevated in Patients with Irritable Bowel Syndrome (IBS) but Largely Unrelated to Symptom Characteristics. *Gastroenterology* 2017, 152(5), S68–S69.
18. Aziz I, **Palsson OS**, Törnblom H, Sperber AD, Whitehead WE, Simren M. The Prevalence and Impact of Overlapping Rome IV Functional Gastrointestinal Disorders on Somatisation, Quality of Life, and Healthcare Utilisation: Results from a Three-Country General Population Study. *Gastroenterology* 2017, 152(5), S116–S117.
19. Zwiener R, Keller C, Robin S, Hyman PE, **Palsson OS**, Saps M, Di Lorenzo C, Shulman RJ, Hyams JS, Nurko S, van Tilburg MA. Prevalence of Rome IV Functional Gastrointestinal Disorders in Children and Adolescents in the United States. *Gastroenterology* 217, 152 (5), S649.
20. Zwiener R, Robin S, Keller C, Hyman PE, Nurko S, Saps M, Di Lorenzo C, Shulman RJ, Hyams JS, **Palsson OS**, van Tilburg MA. Prevalence of Functional Gastrointestinal Disorders in Infants and Toddlers According to the Rome IV Criteria. *Gastroenterology* 217, 152 (5), S649.
21. Chiarioni G, **Palsson O**, Heymen S, Simren M, Cidoni F, Whitehead WE. Abnormal balloon evacuation test does not identify which patients will respond to biofeedback; anorectal manometry or EMG, and structural evaluation are needed. *United European Gastroenterology Journal* October 2016 vol. 4 no. 5 suppl: A475.
22. Chiarioni G, **Palsson O**, Heymen S, Pedrazzani C, Whitehead WE. Levator ani tenderness in patients with dyssynergic defecation. *United European Gastroenterology Journal* October 2016 vol. 4 no. 5 suppl: A477.

23. **Palsson OS**, Simren M, Van Tilburg M, Heymen S, Sperber AD, Whitehead WE. Population prevalence of Rome IV fecal incontinence and associated risk factors in the United States (US), Canada and the United Kingdom (UK). *United European Gastroenterology Journal* October 2016 vol. 4 no. 5 suppl: A478.
24. **Palsson OS**, Simren M, Van Tilburg M, Heymen S, Sperber AD, Whitehead WE. Population prevalence of Rome IV and Rome III functional dyspepsia in the United States (US), Canada and the United Kingdom (UK). *United European Gastroenterology Journal* October 2016 vol. 4 no. 5 suppl: A489.
25. Carrington EV, **Palsson OS**, Simren M, Heymen S, Bharucha A, Rao SC, Lowry A, Gantz M, Gould S, Whitehead WE. Perceptions of current treatments for fecal incontinence. *United European Gastroenterology Journal* October 2016 vol. 4 no. 5 suppl: A479.
26. Carrington EV, **Palsson OS**, Heymen S, Gould S, Simrén M, Whitehead WE. Coping with faecal incontinence: A population study. *United European Gastroenterology Journal*, October 2016; vol. 4, 5 suppl: A1-A156.
27. Whitehead WE, **Palsson OS**, van Tilburg MA, Simren M. Age but Not Sex Affects the Sensitivity of the Rome IV Diagnostic Criteria for IBS. *Gastroenterology* 2016, Vol. 150, Issue 4, S738.
28. Busby-Whitehead J, Whitehead WE, Heymen S, Kizer JS, **Palsson O**, Smren M. Pilot study comparing three methods of screening for fecal incontinence. *United European Gastroenterology Journal* 2016, 4(5) suppl: A132-133.
29. Heymen S, **Palsson OS**, Simren M, Whitehead WE. Conservative Treatment for Fecal Incontinence: Predictors of Treatment Completion and Symptom Improvement. *Gastroenterology* 2016, Vol. 150, Issue 4, S943.
30. **Palsson OS**, van Tilburg MA, Whitehead WE. Families of Irritable Bowel Syndrome (IBS) Patients Have Elevated Prevalence of Chronic Medical Conditions. *Gastroenterology* 2016, Vol. 150, Issue 4, S952.
31. Simren S, Törnblom H, **Palsson OS**, van Tilburg MA, van Oudenhove L, Tack JF, Whitehead WE. Visceral Hypersensitivity is Associated With GI Symptom Severity in Functional GI Disorders: Consistent Findings From Five Different Patient Cohorts. *Gastroenterology* 2016, Vol. 150, Issue 4, S82.
32. Pollard K, Campbell C, Squires MM, **Palsson OS**, van Tilburg MA. Seasonal Variation in Functional Abdominal Pain Is Associated With Changes in Anxiety. *Gastroenterology* 2016, Vol. 150, Issue 4, S100.
33. Simren M, **Palsson OS**, Heymen S, Bajor A, Törnblom H, Whitehead WE. Fecal Incontinence in Irritable Bowel Syndrome (IBS): Prevalence and Associated Factors in Swedish and American Patients. *Gastroenterology* 2016, Vol. 150, Issue 4, S731–S732
34. Simren M, Törnblom H, **Palsson OS**, van Tilburg MA, van Oudenhove L, Whitehead WE, Tack JF. Additive Effect of Pathophysiological Factors on Patient Reported Outcomes in IBS. *Gastroenterology* 2016, Vol. 150, Issue 4, S953.
35. van Tilburg MA, Simren M, **Palsson OS**, Törnblom H, Whitehead WE. Distinct Subtypes of Irritable Bowel Syndrome Are Defined by Psychological Symptoms, Visceral Pain Sensitivity, Stool Consistency, and Motility. *Gastroenterology* 2016, Vol. 150, Issue 4, S954–S955.

36. **Palsson OS**, van Tilburg MA, Simren M, Sperber AD, Whitehead WE. Population Prevalence of Rome IV and Rome III Irritable Bowel Syndrome (IBS) in the United States (US), Canada and the United Kingdom (UK). *Gastroenterology*, Vol. 150, Issue 4, S739–S740.
37. Tack JF, van Oudenhove L, Vanheel H, Carbone F, Törnblom H, **Palsson OS**, van Tilburg MA, Whitehead WE, et al. Additive Effect of Pathophysiological Mechanisms in Determining Symptom Severity in Functional Dyspepsia. *Gastroenterology* 2016, Vol. 150, Issue 4, S58–S59.
38. **Palsson OS**, van Tilburg M, Whitehead WE. Constipation symptoms in the U.S. General Population: Results from the Rome Normative Gastrointestinal Symptoms Survey (RNGSS). *United European Gastroenterology Journal* October 2015, 3(5) suppl: A19.
39. **Palsson OS**, van Tilburg M, Whitehead, WE. Excess medical diagnoses in families of patients with irritable bowel syndrome. *United European Gastroenterology Journal* October 2015, 3(5) suppl: A271.
40. **Palsson OS**, van Tilburg M, Whitehead, WE. Frequencies of both hard and soft stools are major risk factors for fecal incontinence. *United European Gastroenterology Journal* October 2015, 3(5) suppl: A642.
41. Van Tilburg M, **Palsson OS**, Whitehead WE. Principal components analysis confirms four independent etiological factors in irritable bowel syndrome (IBS). *United European Gastroenterology Journal* October 2015 3 (5) suppl: A87.
42. **Palsson OS**, Heymen S, Whitehead WE. Fecal Incontinence Is Associated With Clinically Significant Psychological Distress. *Gastroenterology* 2015, Vol. 148, Issue 4, S-305
43. Heymen S, **Palsson OS**, Whitehead WE. What Makes Discussing Fecal Incontinence (FI) With Providers Difficult? *Gastroenterology* 2015, Vol. 148, Issue 4, S-298
44. **Palsson OS**, Heymen S, Whitehead WE. Non-Gastrointestinal Pain Is Increased in Irritable Bowel Syndrome (IBS) but Does Not Account for Abdominal Pain. *Gastroenterology* 2015, Vol. 148, Issue 4, S-780
45. Pasricha S, Heymen S, **Palsson OS**, Whitehead WE. Men Report More Severe Fecal Incontinence Symptoms Than Women: Patients' Perspective. *Gastroenterology* 2015, Vol. 148, Issue 4, S-302–S-303
46. Riehl ME, Pandolfino JE, **Palsson OS**, Keefer L. The Feasibility and Acceptability of Esophageal-Directed Hypnotherapy for Functional Heartburn. *Gastroenterology* 2015, Vol. 148, Issue 4, S-618–S-619.
47. Smith SB, Maixner W, **Palsson OS**, van Tilburg MA, Kanazawa M, Whitehead WE. FKBP5 Gene Is Associated With IBS Diagnosis. *Gastroenterology* 2015, Vol. 146, Issue 5, S-109
48. Heymen S, **Palsson OS**, Kim SM, Twist S, Whitehead WE. Patient Preference for What Should Be Included in the Definition of Fecal Incontinence. *Gastroenterology* 2015, Vol. 146, Issue 5, S-720–S-721
49. Heymen S, **Palsson OS**, Kim SM, Twist S, Whitehead WE. Patient Preference for Defining Success in Fecal Incontinence Treatment Trials. *Gastroenterology* 2015, Vol. 146, Issue 5, S-721.
50. Ringel Y, **Palsson OS**, Ringel-Kulka T, Whitehead WE. Visceral Hypersensitivity Is an Important Etiological Factor in the Presence and Severity of Abdominal Bloating Symptoms in Patients With Irritable Bowel Syndrome (IBS). *Gastroenterology* 2015, Vol. 148, Issue 4, S-194.

51. van Tilburg MA, **Palsson OS**, Kanazawa M, Barrow DA, Whitehead WE. Cytokine Activation Is Associated With Psychological Distress, Motility and Visceral Hypersensitivity in Irritable Bowel Syndrome (IBS). *Gastroenterology* 2015, Vol. 148, Issue 4, S-38
52. Kanazawa M, **Palsson OS**, van Tilburg MA, Gangarosa LM, Fukudo S, Whitehead WE. Decreased Concentration of Whole Blood Serotonin in IBS With Diarrhea. *Gastroenterology* 2015, Vol. 148, Issue 4, S-779.
53. Heymen S, **Palsson OS**, Pasricha S, Whitehead WE. Fecal Incontinence Severity Index Helps to Identify Patients Who View Their Symptoms As Severe Enough to Consult a Physician. *Gastroenterology* 2015, Vol. 148, Issue 4, S-298.
54. **Palsson O**, Heymen S, Whitehead WE. Abdominal Pain Versus Abdominal Discomfort: Implications for Diagnostic Assessment of Irritable Bowel Syndrome (IBS). *United European Gastroenterology Journal* October 2014 2 (1) suppl: P0405.
55. Heymen S, **Palsson O**, Kim SM, Twist S, Whitehead WE. Patient Preferences for Terminology Used to Identify Fecal Incontinence. *United European Gastroenterology Journal* October 2014 2 (1) suppl: P0419.
56. Whitehead WE, **Palsson OS**, Kim SM, Twist S. Patient Perspectives for Endpoints in Clinical Trials for Fecal Incontinence. *United European Gastroenterology Journal* October 2014 2 (1) suppl: P0986.
57. **Palsson O**, van Tilburg M, Whitehead WE. The Association of Somatization With Irritable Bowel Syndrome (IBS) and Uninvestigated Dyspepsia in the U.S. General Population. *United European Gastroenterology Journal* October 2014 2 (1) suppl: P1573.
58. **Palsson O**, Heymen S, Whitehead WE. Does Perceived Stigma Affect Healthcare Consulting and Quality of Life in Fecal Incontinence? *United European Gastroenterology Journal* October 2014 2 (1) suppl: P1574.
59. Van Tilburg MAL, Hyman PE, Walker LS, Rouster A, **Palsson OS**, Kim SM, Tack JF, Spiller RC, Tack J, Yang Y, Whitehead WE. Prevalence of Infant/Toddler Functional Gastrointestinal Disorders in the U.S.: Results of a National Community Survey of Mothers. *Gastroenterology* 2014, Volume 146 , Issue 5, S-420
60. Van Tilburg MAL, Hyman PE, Walker LS, Rouster A, **Palsson OS**, Kim SM, Tack JF, Spiller RC, Tack J, Yang Y, Whitehead WE. Functional Dyspepsia in Children: Can We Distinguish Epigastric Pain and Postprandial Distress? *Gastroenterology* 2014, Volume 146 , Issue 5 , S-143
61. **Palsson OS**, Van Tilburg MA, Spiegel BM, Tack JF, Spiller RC, Walker LS, Yang Y & Whitehead WE. Uninvestigated Dyspepsia in the U.S. General Population: Results From the ROME Normative Gastrointestinal Symptoms Survey (RNGSS). *Gastroenterology* 2014, Volume 146 , Issue 5 , S-266
62. **Palsson OS**, Van Tilburg MA, Spiegel BM, Tack JF, Spiller RC, Walker LS, Yang Y & Whitehead WE. Fecal Incontinence (FI) Prevalence and Associated Gastrointestinal Risk Factors in the U.S. General Population. *Gastroenterology* 2014, Volume 146 , Issue 5 , S-155
63. **Palsson OS**, Van Tilburg MA, Spiegel BM, Tack JF, Spiller RC, Walker LS, Yang Y & Whitehead WE. Irritable Bowel Syndrome (IBS) Prevalence in the U.S. General Population: Results From the Rome Normative Gastrointestinal Symptoms Survey (RNGSS). *Gastroenterology* 2014, Volume 146 , Issue 5 , S-179

64. Van Tilburg MAL, Hyman PE, Walker LS, Rouster A, **Palsson OS**, Kim SM, Tack JF, Spiller RC, Tack J, Yang Y, Whitehead WE. Gastroenterology 2014, Volume 146, Issue 5, S-143 - S-144
65. Heymen S, **Palsson OS**, Kim SM, Twist S, Whitehead WE. Patient Preference for Defining Success in Fecal Incontinence Treatment Trials. Gastroenterology 2014, Volume 146 , Issue 5, S-721
66. Heymen S, **Palsson OS**, Kim SM, Twist S, Whitehead WE. Patient Preference for What Should Be Included in the Definition of Fecal Incontinence. Gastroenterology 2014, Volume 146 , Issue 5, S-720 - S-721
67. Faurot KR, Gaylord S, **Palsson OS**, Garland EL, Mann D, Whitehead WE. Mindfulness Meditation Has Long-Term Therapeutic Benefits in Women With Irritable Bowel Syndrome (IBS): Follow-Up Results From a Randomized Controlled Trial. Gastroenterology 2014, Volume 146 , Issue 5, S-124.
68. Smith SB, Maixner W, **Palsson OS**, Van Tilburg MAL, Kanazawa M, Whitehead WE. 584 FKBP5 Gene Is Associated With IBS Diagnosis. Gastroenterology 2014, Volume 146 , Issue 5, S-109.
69. **Palsson OS**, Baggish J, Whitehead WE. Symptom Episode Patterns in Irritable Bowel Syndrome (IBS). Gastroenterology 2013, Vol. 144, Issue 5, Supplement 1, Page S-919
70. Whitehead WE, **Palsson OS**, Cascade E. Validation of Response Scales for ROME Diagnostic Questionnaire. Gastroenterology 2013, Vol. 144, Issue 5, Supplement 1, Page S-916.
71. Kanazawa M, Whitehead WE, **Palsson OS**, Shinosaki M, Okuyama Y, Fukudo S. Comparison of Agreement Between Reports of Satisfactory Relief and Global Improvement in Patients With IBS: A Cross-Cultural Study Between the US and Japan. Gastroenterology 2013, Vol. 144, Issue 5, Supplement 1, Pages S-265-S-266.
72. Shen J, **Palsson OS**, Van Tilburg MAL. Seasonal Variation in Functional Abdominal Pain Is Associated With Changes in Anxiety, Sleep, Parental Response to Pain, Eating and Exercise. Gastroenterology 2013, Vol. 144, Issue 5, Supplement 1, Pages S-400-S-401.
73. Ringel T, Van Tilburg MAL, **Palsson OS**, Thurlow K, Ramsden C, Ringel Y. Food-Specific IgG4 Antibody Titers in Subjects With Food Hypersensitivity. Gastroenterology 2013, Vol. 144, Issue 5, Supplement 1, Page S-928.
74. **Palsson OS**, Turner MJ, Baggish JS, Whitehead WE. The Significance of Days with No Stool in Irritable Bowel Syndrome. Gastroenterology 2012, Vol. 142, Issue 5, Supplement 1, Page S-818.
75. Kanazawa M, Whitehead WE, **Palsson OS**, Turner MJ, Shnozaki M, Okuyama Y, Fukudo S. Medical Care for Irritable Bowel Syndrome (IBS) in Japan Compared to the U.S. Gastroenterology 2012, Vol. 142, Issue 5, Supplement 1, Page S-10.
76. Van Tilburg MA, **Palsson OS**, Whitehead WE. Which Psychological Factors Exacerbate Irritable Bowel Syndrome? Test of a Comprehensive Model. Gastroenterology 2012, Vol. 142, Issue 5, Supplement 1, Page S-10.
77. Kanazawa M, **Palsson OS**, Turner MJ, Gangarosa LM, Fukudo S, Whitehead WE. Visceral Pain Sensitivity to Intraluminal Distension in the Rectum is Heightened More Than That in the Descending Colon in Patients with Irritable Bowel Syndrome (IBS). Gastroenterology 2012, Vol. 142, Issue 5, Supplement 1, Page S-704.

78. Heymen S, **Palsson OS**, Turner MJ, Whitehead WE. What is the Best Case Definition for Identifying Patients with Chronic Constipation? *Gastroenterology* 2012, In: AGA (Eds.) *Gastroenterology* 2012, Vol. 142, Issue 5, Supplement 1, Page S-816.
79. Ringebl Y, Ringel-Kulka T, Ferrier L, Siddle JP, **Palsson OS**, Bueno L. Fecal Cysteine Protease Activity in Patients With Irritable Bowel Syndrome -Clinical and Physiological Aspects. *Gastroenterology* 2012, Vol. 142, Issue 5, Supplement 1, Page S-833.
80. Ringel-Kulka T, Thurlow K, Siddle JP, **Palsson OS**, Ringel Y. Over and Under Reporting of Abdominal Pain and Quality-of-Life in Patient and Non-Patients With Functional Bowel Symptoms. *Gastroenterology* 2012 Vol. 142, Issue 5, Supplement 1, Page S-822
81. Gaylord S, **Palsson OS**, Garland E, Faurot K, Coble RS, Mann D, Whitehead WE. Therapeutic Impact of Mindfulness Meditation on Irritable Bowel Syndrome (IBS): Results of a Randomized Controlled Trial. *Gastroenterology* 2011, 140 ed. 5(suppl1):S-50.
82. Heymen S, **Palsson OS**, Gangarosa LM, Girdler S, Whitehead WE. Diffuse Noxious Inhibitory Controls (DNIC) Are Compromised in Patients With Irritable Bowel Syndrome (IBS) Compared to Healthy Controls (HC). *Gastroenterology* 2011, 140 ed. 5(suppl1):S-538.
83. Heymen S, **Palsson OS**, Maixner W, Gangarosa LM, Girdler S, Whitehead WE. Temporal Summation in Patients With Irritable Bowel Syndrome (IBS) Compared to Healthy Controls (HC). *Gastroenterology* 2011, 140 ed. 5(suppl1):S-539.
84. Kanazawa M, Whitehead WE, Levy RL, Seino S, Tatsuta N, **Palsson OS**, Turner MJ, Endo Y, Nakai K, Satoh H, Fukudo S. Increased Stomach Aches in Children Are Associated With Parent IBS Status and Maladaptive Parenting in Japan. *Gastroenterology* 2011, 140 ed. 5(suppl1):S-465.
85. Markland A, **Palsson OS**, Goode PS, Burgio K, Busby-Whitehead J, Whitehead WE. Association of low dietary intake of fiber and liquids with constipation: Evidence from the National Health and Examination Survey (NHANES). *Gastroenterology* 2011, 140 ed. 5(suppl1):S-152.
86. **Palsson OS**, Turner MJ, Baggish JS, Whitehead WE. How Good Are Individuals at Predicting Diarrhea Based on Perceived Triggers and Warning Sensations?: A Diary Study. *Gastroenterology* 2011, 140 ed. 5(suppl1):S-795.
87. **Palsson OS**, Turner MJ, Tucker J, Whitehead WE. Is the Effect of Lubiprostone on Clinical Pain Mediated by Decreases in Visceral Pain Sensitivity? *Gastroenterology* 2011, 140 ed. 5(suppl1):S-3.
88. Robinson BL, Matthews C, **Palsson OS**, Geller E, Turner MJ, Parnell B, Crane A, Jannelli M, Wells E, Connolly A, Whitehead WE. Influence of Stool Consistency, Urgency, and Obstetric History on Fecal Incontinence. *Gastroenterology* 2011, 140 ed. 5(suppl1):S-797.
89. Tanaka Y, Kanazawa M, Hill CE, **Palsson OS**, Van Tilburg MA, Turner MJ, Gangarosa LM, Fukudo S, Drossman DA, Whitehead WE. Increased Postprandial Colonic Motility is Associated With Sympathetic Nerve Activity in Patients With Irritable Bowel Syndrome. *Gastroenterology* 2011, 140 ed. 5(suppl1):S-527.
90. Van Tilburg MA, **Palsson OS**, Kanazawa M, Turner MJ, Whitehead WE. Excess Co-Morbidity in IBS: Increased Neural Sensitivity or Response Bias? *Gastroenterology* 2011, 140 ed. 5(suppl1):S-93.
91. Wong RK, Van Tilburg MA, Sweat D, Squires M, **Palsson OS**, Turner MJ, Whitehead WE. Predictive Factors in the Development of Post-Infectious Irritable Bowel Syndrome. *Gastroenterology* 2011, 140 ed. 5(suppl1):S-527.

92. Kanazawa M, **Palsson OS**, Van Tilburg MAL, Gangarosa LM, Fukudo S, Drossman DA, Whitehead WE. Motility Response to Colonic Distention is Increased in Post-Infectious Irritable Bowel Syndrome (PI-IBS). *Gastroenterology* 2010;138:S-91.
93. **Palsson OS**, Turner MJ, Heymen S, Weinland SR, Tucker J, Keck L, Whitehead WE. Developing a Screening Questionnaire for Visceral Hypersensitivity. *Gastroenterology* 2010;138: S-144.
94. **Palsson OS**, Turner MJ, Baggish JS, Whitehead WE. Anticipating Diarrhea: Triggers, Warnings, and Prevention. *Gastroenterology* 2010;138:S-382.
95. Heymen S, **Palsson OS**, Turner MJ, Tucker J, Palmer MH, Busby-Whitehead J, Whitehead WE. Residents at Continuing Care Residential Centers (CCRC) Who Consult With Their Doctors Regarding the Presence of Fecal Incontinence (FI) Have Significantly Lower Quality of Life (QOL) Scores. *Gastroenterology* 2010;138:S-542.
96. Ringel-Kulka T, Maier DM, **Palsson OS**, Ringel Y. Characterization and Comparison of Patients Versus Non-Patients With Functional Bowel Symptoms in the General Population. *Gastroenterology* 2010;138:S-384.
97. KA Nyrop KA, Grover M, Busby-Whitehead J, **Palsson OS**, Heymen S, Palmer MH, Goode PS, Turner M, Whitehead WE (2009). Physician attributes that influence the decision to refer a patient with fecal incontinence to a nursing home. *JAGS Mar; Vol. 57 (Suppl 1): S48*.
98. Busby-Whitehead J, Grover M, Palmer MH, Heymen S, **Palsson OS**, Goode PS, Turner M, Whitehead WE (2009). Social circumstances influence the decision to refer an elderly patient with fecal incontinence to a nursing home. *JAGS Mar; Vol. 57 (Suppl 1): S48*.
99. **Palsson OS**, Turner MJ, Levy RL, Feld AD, Von Korff M, Whitehead WE. The ROME III Functional Constipation Criteria Miss 80% of Clinical Constipation Cases. *Gastroenterology* 2009; 136 (Suppl 1):M1233
100. Van Tilburg MA, Turner MJ, **Palsson OS**, Kanazawa M, Whitehead WE. Reduced Symptoms and Visceral Sensitivity Is Related to Menstrual Cycle Changes in IBS. *Gastroenterology* 2009; 136 (Suppl 1):1056
101. Grover M, Busby-Whitehead J, Palmer MH, Heymen S, **Palsson OS**, Goode PS, Turner MJ & Whitehead WE. Survey of Geriatricians on the Impact of Fecal Incontinence on Nursing Home Referral. *Gastroenterology* 2009; 136 (Suppl 1):S1236
102. Ringel-Kulka T, **Palsson OS**, Galanko J, Maier DM & Ringel Y. Clinical and Physiological Effects of Yogurt Drink Containing the Probiotic Bacteria *Bifidobacterium lactis* Bb12 and Prebiotic Inulin in Subjects with Functional Bowel Symptoms. *Gastroenterology* 2009; 136 (Suppl 1):1076
103. **Palsson OS**, Turner MJ, Baggish JS & Whitehead WE. Defining Episodes of Diarrhea in Irritable Bowel Syndrome (IBS). *Gastroenterology* 2009; 136 (Suppl 1):M1206
104. Kanazawa M, **Palsson OS**, Van Tilburg MA, Turner MJ, Thiwan SIM, Gangarosa LM, Chitkara DK, Fukudo S, Drossman DA & Whitehead WE. A History of Sexual Abuse and Catastrophizing Have An Impact On IBS Symptom Severity That Is Unrelated to Psychological Distress. *Gastroenterology* 2009; 136 (Suppl 1):763
105. Hill CE, **Palsson OS**, Kanazawa M, Turner MJ, Whitehead WE. IBS Patients Show Parasympathetic Dominance in Heart Rate Variability Compared to Healthy Controls. *Gastroenterology* 2009; 136 (Suppl 1):M1213

106. **Palsson OS**, Turner MJ, Baggish JS, Whitehead WE. Characterizing Diarrhea in Irritable Bowel Syndrome (IBS). *Gastroenterology* 2009; 136 (Suppl 1):M1223
107. Wong RK, **Palsson OS**, Turner MJ, Levy RL, Feld AD, Von Korff M, & Whitehead WE. Are Functional Constipation (FC) and Constipation Subtype Irritable Bowel Syndrome (IBS-C) Different Entities When Diagnosed By ROME III Criteria? *Gastroenterology* 2009; 136 (Suppl 1):M1224
108. Ringel Y, Carroll IM, **Palsson OS**, Sartor RB. Substance P and Its Mucosal Receptors - Possible Mediators of Inflammation and Noxious Sensation in Irritable Bowel Syndrome. *Gastroenterology* 2009; 136 (Suppl 1):S1249
109. Kanazawa M, Tana C, Watanabe S, **Palsson OS**, Whitehead WE, Fukudo S. High-Sensitive C-Reactive Protein May Be One of Blood Biomarkers for Visceral Hypersensitivity in Irritable Bowel Syndrome (IBS). *Gastroenterology* 2009; 136 (Suppl 1):W1692
110. Grover M, **Palsson O**, Levy R, Feld A, Von Korff M, Whitehead, WE. Chronic constipation: health care consulters vs non-consulters. *Neurogastroenterology & Motility* 2008; 20 (Suppl. 2): 24-25.
111. Ringel-Kulka T, **Palsson OS**, Maier D, Ringel Y. The effect of daily consumption of probiotic bacteria *Bifidobacterium lactis* BB12 and prebiotic inulin on colonic transit time in subjects with functional bowel symptoms. *Neurogastroenterology & Motility* 2008; 20 (Suppl. 2): 94.
112. Bobzien, B, Ringel-Kulka T, Covington M, **Palsson OS**, Ringel Y. Long-term gastrointestinal symptoms following acute enteric viral infections. *Neurogastroenterology & Motility* 2008; 20 (Suppl. 2): 137.
113. Gaylord, S, **Palsson, OS**, Faurot K, Garland E, Coble R, Mann JD, Whitehead WE. Relationship between dispositional mindfulness and disease severity, quality of life and psychological well-being in women with irritable bowel syndrome (IBS). (Submitted abstract, 2009 North American Research Conference on Complementary and Integrative Medicine)
114. **Palsson OS**, Naliboff BD, Turner MJ, Levy RL, Feld AD, Von Korff M, Whitehead WE. Both Bowel Symptom Severity and Visceral Anxiety are Major Determinants of the Quality of Life Impact of Constipation. *Gastroenterology* 2008;134(4)Suppl 1:A416
115. **Palsson OS**, Turner MJ, Levy RL, Feld AD, Von Korff M, Drossman DA, Whitehead WE. The ROME III Questionnaire Functional Constipation Module as a Constipation Severity Scale. *Gastroenterology* 2008;134(4)Suppl 1:A421.
116. **Palsson OS**, Van Tilburg MA, Kanazawa M, Chitkara DK, Gangarosa LM, Drossman DA, Whitehead WE. Persistence of the Rome Diagnostic Symptoms for Irritable Bowel Syndrome. *Gastroenterology* 2008;134(4)Suppl 1:A421-22.
117. Grover M, Kanazawa M, Chitkara DK, Gangarosa LM, **Palsson OS**, Drossman DA, Turner MJ, Whitehead WE. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Association with Colon Motility, Bowel Symptoms, and Psychological Distress. *Gastroenterology* 2008;134(4)Suppl 1:A680.
118. Heymen S, **Palsson OS**, Von Korff M, Levy RL, Turner MJ, Whitehead WE. Health Care Costs Associated with Fecal Incontinence. *Gastroenterology* 2008;134(4)Suppl 1:A279.
119. Nguyen TV, **Palsson OS**, Von Korff M, Feld AD, Levy RL, Turner MJ, Whitehead WE. Health Care Costs and Utilization in Patients with Chronic Constipation. *Gastroenterology* 2008;134(4)Suppl 1:A280.

120. Ringel Y, **Palsson OS**, Leyer G, Causey S, Yeskel SE, Faber SM, Ringel-Kulka T. Probiotic bacteria *Lactobacillus Acidophilus Ncfm* and *Bifidobacterium Lactis Bi07* improve symptoms of bloating in patients with functional bowel disorders (FBD). *Gastroenterology* 2008;134(4)Suppl 1:A549.
121. Ringel Y, Ringel A, **Palsson OS**, Kanazawa M, Whitehead WE. Meal Induced Symptoms in Patients with Irritable Bowel Syndrome – Clinical and Physiological Characteristics. *Gastroenterology* 2008;134(4)Suppl 1:A681.
122. **Palsson OS**, Turner, MJ, Levy, Feld AD, Von Korff, M, Whitehead, WE. Prevalence and Predictors of Non-Consulting for Chronic Constipation. *American Journal of Gastroenterology* 2007; 102 Suppl 2: S512.
123. Nguyen T, **Palsson OS**, Von Korff M, Feld AD, Levy R, Turner M, Whitehead WE. Satisfaction with Laxatives in Chronic Constipation and Irritable Bowel with Constipation. *American Journal of Gastroenterology* 2007; 102 Suppl 2: S516-17.
124. **Palsson OS**, Van Tilburg MAL, Levy RL, Turner MJ, Chitkara DK, Gangarosa LM, Kanazawa M, Whitehead WE. Excess Medical Diagnoses in Families of Irritable Bowel Syndrome (IBS) Patients. *Gastroenterology* 2007;132 (4):A520.
125. **Palsson OS**, Kanazawa M, Van Tilburg MAL, Thiwan SIM, Ringel Y, Dorn SD, Gangarosa LM, Turner MJ, Drossman DA. Whitehead WE. Determinants of Irritable Bowel Syndrome Severity. *Gastroenterology* 2007;132 (4):A677-678.
126. Jones MP, Havlicek T, Keefer L, Bratten J, Norton NJ, Crowell MD, Levy RL, **Palsson OS**. The Perceived Stigma Scale in IBS: A Preliminary Report on Development and Validation. *Gastroenterology* 2007;132 (4):A521.
127. **Palsson OS**, Ringel Y, Van Tilburg MAL, Gangarosa LM, Turner MJ, Kanazawa M, Thiwan SIM, Drossman DA, Whitehead WE. Impact of Fecal Incontinence on Irritable Bowel Syndrome. *Gastroenterology* 2007;132 (4):A678.
128. Kanazawa M, **Palsson OS**, Thiwan SIM, Turner MJ, Van Tilburg MAL, Fukudo S, Drossman DA, Whitehead WE. Differences in Visceral Hypersensitivity and Hypercontractivity to Intraluminal Distention between Subtypes of Bowel Movement in Irritable Bowel Syndrome (IBS). *Gastroenterology* 2007;132 (4):A458-459.
129. Kanazawa M, **Palsson OS**, Shinozaki M, Sagami Y, Endo Y, Shoji T, Hongo M, Whitehead WE, Fukudo S. Comparison of Comorbidity in Japanese and U.S. Patients with Irritable Bowel Syndrome. *Gastroenterology* 2007;132 (4):A680-681.
130. Van Tilburg MAL, **Palsson OS**, Turner MJ, Chitkara DK, Ulshen M, Whitehead WE. Self Administered Guided Imagery Used at Home is an Effective Treatment for Functional Abdominal Pain in Children. *Gastroenterology* 2007;132 (4):A59.
131. Whitehead WE, **Palsson OS**, Kanazawa M, Gangarosa LM, Thiwan SIM, Drossman DA, Van Tilburg MAL, Chitkara DK, Dorn SD, Ringel Y, Turner MJ. Cluster Analysis Evidence that Irritable Bowel Syndrome is not a Single Disorder but a Collection of Distinct Syndromes. *Gastroenterology* 2007;132 (4):A148.
132. Dorn SD, **Palsson OS**, Thiwan SIM, Kanazawa M, Clark WC, van Tilburg MAL, Drossman DA, Scarlett Y, Levy RL, Ringel Y, Crowell MD, Olden KW, Whitehead WE. Increased colonic sensitivity in irritable bowel syndrome is the result of increased perceptual response bias rather than increased perceptual sensitivity. *Gastroenterology* 2006;128(4), Suppl 2: A-443.

133. Kanazawa M, **Palsson OS**, Thiwan SIM, Turner MJ, van Tilburg M, Crowell MD, Fukudo S, Drossman DA, Whitehead WE. Irritable bowel syndrome (IBS) patients show hyper-reactive motility responses to intraluminal distention which are unrelated to pain hypersensitivity. *Gastroenterology* 2006, 130(4), Suppl.2:A-290.
134. Van Tilburg MAL, **Palsson OS**, Chitkara DK, Whitehead WE. Medical consultation for children's chronic stomachaches is related to a belief that the symptoms have a physical cause but is not related to anxiety about serious missed diagnosis. *Gastroenterology* 2006;130(4), Suppl.2: A-501.
135. Van Tilburg MAL, **Palsson OS**, Whitehead WE. Somatization trait and somatization disorder have different impacts on IBS. *Gastroenterology* 2006;130(4), Suppl.2: A-503.
136. Whitehead WE, Palsson OS, Thiwan SIM, Keku TO, Kanazawa M, Fukudo S, van Tilburg MAL, Peacock J, Barnes J, Turner MJ. Short-allele serotonin transporter gene polymorphism is associated with elevated serotonin and is less common in IBS with constipation compared to healthy controls. *Gastroenterology* 2006;130(4), Suppl.2: A-513.
137. Heymen S, van Tilburg M, Thiwan S, **Palsson O**, Young SL, Whitehead WE. Exacerbation of irritable bowel syndrome symptoms during menses is associated with increased prostaglandin (PGE2) levels. *Neurogastroenterology & Motility* 2006;18(8): 674.
138. Thiwan SIM, **Palsson OS**, Turner MJ, Whitehead WE. Subjective bloating is not correlated with intestinal gas production but is weakly correlated with abdominal distention. *Gastroenterology* 2006, 130(4), Suppl.2: A-506.
139. Thiwan SIM, **Palsson OS**, Turner MJ, Whitehead WE. Lactose malabsorption, small bowel bacterial overgrowth and celiac disease in IBS patients. *Gastroenterology* 2006, 130(4), Suppl.2: A-506.
140. Thiwan SIM, **Palsson OS**, Turner MJ, Whitehead WE. Elevated breath methane in constipation. *Gastroenterology* 2006, 130(4), Suppl.2: A-509.
141. Halpert A, Dalton C, **Palsson O**, Hu Y, Morris C, Bangdiwala S, Norton N, Drossman D. What patients with irritable bowel syndrome (IBS) expect from their health care providers. National Survey on IBS Educational Needs and Expectations. *Gastroenterology* 2006, 130(4), Suppl.2: A505.
142. Van Tilburg, MAL, **Palsson OS**, Levy RL, Whitehead WE. Parental Worries about Recurrent Abdominal Pain. *Journal of Pediatric Gastroenterology and Nutrition* 2005, 41 (suppl1):S79.
143. **Palsson OS**, Levy RL, Feld AD, Von Korff M, Turner MJ, Whitehead WE. Patient characteristics determining clinical diagnosis of constipation-predominant IBS (IBS-C) vs. chronic constipation (CC). *American Journal of Gastroenterology* 2005, 100(10), Suppl: S338.
144. **Palsson OS**, Levy RL, Feld, AD, Von Korff M, Turner MJ, & Whitehead WE. Which symptoms predict satisfaction with treatment and improved quality of life in irritable bowel syndrome (IBS)? *American Journal of Gastroenterology* 2005, 100(10), Suppl: S341-342.
145. **Palsson OS**, Levy RL, Feld AD, Von Korff M, Turner MJ, Whitehead WE. Do comorbid dyspepsia and reflux symptoms affect morbidity, utilization, and outcome in irritable bowel syndrome? *American Journal of Gastroenterology* 2005, 100(10), Suppl: S338.
146. **Palsson OS**, Levy RL., Feld, AD, Von Korff M., Turner, MJ, Whitehead WE. Which medications and food supplements are associated with bloating in patients with functional bowel disorders? *American Journal of Gastroenterology* 2005, 100(10), Suppl: S338-339.

147. **Palsson OS**, Levy RL, Feld AD, Von Korff M., Turner MJ, Whitehead WE. Why Do Irritable Bowel Syndrome Patients Take Multiple Drugs And What Are The Associated Costs? *American Journal of Gastroenterology* 2005, 100(10), Suppl., S335.
148. Kanasawa M, Drossman DA, Shinozaki M, Sagami Y, Endo Y, **Palsson OS**, Hongo M, Whitehead WE. Translation and validation of a Japanese version of the Irritable Bowel Syndrome-Quality of Life Measure (IBS-QOL-J). *American Journal of Gastroenterology* 2005, 100(10), Suppl., S334.
149. Halpert A, Dalton C, Hu Y, Morris C, **Palsson O**, Norton N, Drossman DA. National survey on patient education in irritable bowel syndrome (IBS). *American Journal of Gastroenterology* 2005, 100(10), Suppl., S336.
150. Whitehead WE, **Palsson OS**, Levy RL, von Korff M, Feld AD, Drossman DA, Turner MJ. Serious misclassifications (gastrointestinal cancer, IBD, or malabsorption) are infrequent in patients with a clinical diagnosis of IBS. *Gastroenterology* 2005;128:A463.
151. Thiwan S, **Palsson OS**, Turner MJ, Whitehead WE. Responsiveness of the bloating severity Questionnaire (BLSQ). *Gastroenterology* 2005;128:A462.
152. **Palsson OS**, Levy RL, Von Korff M, Feld AD, Barghout V, Turner MJ, Whitehead WE. Over-the-counter (OTC) and complementary /alternative medicine (CAM) expenses of irritable bowel syndrome (IBS) patients. *Gastroenterology* 2005;128:A461.
153. Thiwan S, **Palsson OS**, Turner MJ, Whitehead WE. What is the optimal response scale on a questionnaire to elicit the subject's responses to the ROME II criteria for IBS? *Gastroenterology* 2005;128:A461.
154. Whitehead WE, **Palsson OS**, Levy RL, Von Korff M, Feld AD, Drossman DA, Turner MJ. Sensitivity and specificity of red flags for identifying gastrointestinal cancer, IBD, or malabsorption in patients with a functional gastrointestinal disorder (FGID). *Gastroenterology* 2005;128:A462.
155. **Palsson OS**, Whitehead WE, Levy RL, Feld, AD, Von Korff,M., Turner, MJ. Constipation less effectively treated than other functional bowel problems in a health maintenance organization (HMO). *American Journal of Gastroenterology* 2004, 99(10) Suppl:S287.
156. **Palsson OS**, Thiwan SM, Whitehead WE, Turner MJ. Development of a bloating severity questionnaire. *American Journal of Gastroenterology* 2004, 99(10) Suppl:S286.
157. Thiwan SM, **Palsson OS**, Whitehead WE, Turner MJ. Assessing the sensitivity of the bloating severity questionnaire (BLSQ). *American Journal of Gastroenterology* 2004, 99(10) Suppl:S286-S287.
158. Whitehead WE, Levy RL, Von Korff M., Feld AD, **Palsson OS**. Workup for first-time consulters costs less than continuing care for IBS. *American Journal of Gastroenterology* 2004, 99(10) Suppl:S239.
159. Whitehead WE, Levy RL, Von Korff M, Feld AD, Kahler K., Barghout V, **Palsson OS**. Relationship between satisfaction with treatment outcome and cost in IBS patients. *American Journal of Gastroenterology* 2004,99(10) Suppl:S239.
160. Whitehead WE, **Palsson OS**, Levy RL, Feld AD, Von Korff M, Turner MJ, Drossman DA, Crowell MD. Identification of irritable bowel (IBS) patients with alternating bowel habits. *Gastroenterology* 2004, 126(4), Suppl 2: A-369.

161. Van Tilburg MAL, Venepalli N, **Palsson OS**, Whitehead WE. The parental worries of recurrent abdominal pain questionnaire: Do parental cognitions distinguish consultants from non-consulters? *Gastroenterology* 2004, 126(4), Suppl 2:A-372.
162. **Palsson OS**, Whitehead WE, Levy RL, Feld AD, Dennis EH, Barghout VE, Turner MJ. Constipation is often undiagnosed or misdiagnosed in outpatient clinics: diagnosis of constipation is associated with better outcomes. *Gastroenterology* 2004, 126(4), Suppl 2: A-606.
163. **Palsson OS**, Whitehead WE, Barghout V, Turner MJ. Medical diagnoses in functional dyspepsia patients. *Gastroenterology* 2004, 126(4), Suppl 2: A-604.
164. Whitehead WE, **Palsson OS**, Levy RL, Feld AD, Von Korff M, Shetzline M, Turner MJ. Types of medications used for irritable bowel syndrome (IBS). *Gastroenterology* 2004, 126(4), Suppl 2: A-642.
165. Whitehead WE, **Palsson OS**, Levy RL, Feld AD, Von Korff M, Turner MJ. "Satisfactory relief" is an unsatisfactory method of defining an irritable bowel syndrome (IBS) responder. *Gastroenterology* 2004, 126(4), Suppl 2: A-88.
166. Whitehead WE, **Palsson OS**, Levy RL, Feld AD, Von Korff M, Turner MJ. Psychological symptoms do not predict symptom improvement in standard medical care for irritable bowel syndrome (IBS). *Gastroenterology* 2004, 126(4), Suppl 2:A-88.
167. Whitehead WE, Van Tilburg MAL, **Palsson OS**. Development of the parental worries of recurrent abdominal pain questionnaire. *American Journal of Gastroenterology* 2003, 98:S273.
168. Whitehead, WE, **Palsson OS**. Barghout VE, Turner MJ. Mechanism of diagnosis and frequency of endoscopy in functional dyspepsia. *American Journal of Gastroenterology* 2003, 98:S303.
169. Whitehead WE, **Palsson OS**, Levy RL, Von Korff M, Feld AD, Garner M. What constitutes standard medical care for irritable bowel syndrome (IBS) in U.S. primary care and gastroenterology clinics? *American Journal of Gastroenterology* 2003, 98:S272-S273.
170. **Palsson OS**, Whitehead WE & Turner MJ (2003). Hypnosis home treatment for irritable bowel syndrome: Exploratory study. *American Journal of Gastroenterology* 2003, 98:S274.
171. **Palsson OS**, Whitehead WE, Barghout V., Levy RL, Feld AD, Von Korff M., Garner M, Drossman DA. Turner MJ. IBS severity and health-related quality of life improve with age in women but not in men. *American Journal of Gastroenterology* 2003, 98:S272.
172. **Palsson OS**, Turner MJ, van Tilburg MAL, Kanasawa M, Whitehead WE. Survey of the effects of changes in female sex hormones on irritable bowel syndrome. *Gastroenterology* 2003, 124 (Suppl 1): A396.
173. **Palsson OS**, Levy RL, Von Korff M, Feld A., Turner MJ, Whitehead, WE. Comorbidity and psychological distress in irritable bowel syndrome (IBS). *Gastroenterology* 2003, 124 (Suppl 1): A388.
174. Whitehead WE, **Palsson OS**, Levy RL, Feld AD, Von Korff, M, Drossman, DA, Turner MJ. Agreement of Rome criteria with clinical diagnosis of irritable bowel (IBS). *Gastroenterology* 2003, 124 (Suppl 1): A397.
175. **Palsson OS**, Levy RL, Von Korff M, Feld AD, Turner MJ, Whitehead WE. Alternative medicine and home remedy use in irritable bowel syndrome (IBS) is related to bloating and diarrhea. *Gastroenterology* 2003, 124 (Suppl 1): A391.

176. Whitehead WE, **Palsson OS**, Von Korff M, Levy RL, Feld AD, Turner MJ. Excess comorbidity in irritable bowel syndrome is related to hypervigilance. *Gastroenterology* 2003, 124 (Suppl 1): A391.
177. Feld AD, Von Korff M, Levy RL, **Palsson OS**, Turner MJ, Whitehead WE. Excess surgery in irritable bowel syndrome (IBS). *Gastroenterology* 2003, 124 (Suppl 1): A388.
178. Whitehead WE, **Palsson OS**, Levy RL., Von Korff M., Feld AD, Turner MJ. Comorbid psychiatric disorders in irritable bowel (IBS) and inflammatory bowel disease (IBD). *Gastroenterology* 2003, 124 (Suppl 1): A398.
179. **Palsson OS**, Jones KR, Turner MJ, Drossman DA, Whitehead WE. Development of specific questionnaires to assess somatization and comorbid diagnoses in irritable bowel syndrome (IBS). *Gastroenterology* 2002, 122 (Suppl 1): A502.
180. **Palsson, OS**, Jones KR, Turner MJ., Drossman DA, Whitehead WE. Impact of somatization and comorbid medical conditions on health care utilization, disability, and quality of life in irritable bowel syndrome (IBS). *Gastroenterology* 2002, 122 (Suppl 1): A501-502.
181. Whitehead, WE, **Palsson OS**, Jones KR, Turner MJ, Drossman DA. Role of parental modeling in somatization of adults with irritable bowel syndrome. *Gastroenterology* 2002, 122 (Suppl 1) A502.
182. **Palsson OS**, Turner MJ, Davies MJ, Johnson DA, Whitehead WE. Vasoactive intestinal peptide levels are elevated in the blood plasma of irritable bowel syndrome (IBS) patients. *Gastroenterology* 2001, 120 (Suppl 1); A718-A719.
183. Jones KR., **Palsson OS**, Levy RL, Feld AD., Longstreth GF, Bradshaw BH, Drossman DA., Whitehead WE. Somatization in irritable bowel syndrome. *Gastroenterology* 2001, 120 (Suppl 1); A639.
184. Jones KR., **Palsson OS**, Levy RL, Feld AD, Longstreth, GF, Bradshaw BH, Drossman DA., Whitehead, WE. Comorbid disorders and symptoms in irritable bowel syndrome (IBS) Compared to other gastroenterology patients. *Gastroenterology* 2001, 120, A66.
185. Levy RL, Whitehead WE, Feld AD, Longstreth GF, **Palsson OS**, Jones KR. (2001). Psychological symptoms correlate with abdominal pain more in females than in males. *Gastroenterology*, 120, A639-640.
186. **Palsson OS**, Turner MJ, Johnson DA. (2000). Hypnotherapy for irritable bowel syndrome: Symptom improvement and autonomic nervous system effects. *Gastroenterology* 2000, 118 (4) A174.
187. **Palsson OS**, Turner, MJ, Johnson DA. (2000). Psychological threat perception and symptom severity in patients with irritable bowel syndrome. *Gastroenterology* 2000, 118 (4), A617.
188. **Palsson, OS**, Nussen J. (2000). Quantitative electroencephalographic (QEEG) activity, health history and emotional distress. *Proceedings of the 31st Annual Meeting of the Association for Applied Psychophysiology and Biofeedback*, 2000, Denver, CO: 83-86.
189. **Palsson OS**, Reavis SL. Psychological traits modulating threat perception and immune system. *Proceedings of the 31st Annual Meeting of the Association for Applied Psychophysiology and Biofeedback*, 2000, Denver, CO, 87-90.
190. **Palsson OS**, Downing BK. Psychophysiological characteristics of patients with irritable bowel syndrome". *Applied Psychophysiology and Biofeedback* 1999, 25:88.

191. **Palsson OS**, Downing BK. Gender matters: Psychophysiological data on ninety healthy men and women. *Applied Psychophysiology and Biofeedback* 1999, 25:89.
192. **Palsson OS**, Davies SM, & Downing BK. Psychological modulators of cardiovascular reactions to cognitive stress. *Applied Psychophysiology and Biofeedback* 1998, 23 (2):108.
193. **Palsson OS**, Boregowda SC, Downing BK. The relationship between the Objective Stress Index (OSI) and stress-related physical symptoms. *Applied Psychophysiology and Biofeedback* 1998, 23 (2):125.
194. Whitehead WE, **Palsson OS**, Levy RL, Gibbs NA, Meyer KB. Patients with irritable bowel syndrome pay selective attention to gastrointestinal sensations. *Gastroenterology* 1998, 114, A859.
195. Whitehead WE, Burnett CE, **Palsson OS**, Drossman DA. Can symptoms distinguish subtypes of constipation? *Gastroenterology* 1998, 114, A729.
196. Burnett C, **Palsson O**, Whitehead WE, Drossman D. Psychological distress and impaired quality of life in patients with functional anorectal disorders. *Gastroenterology* 1998, 114, A859.
197. Boregowda SC, **Palsson OS**, Tiwari SN, Bartolome-Rull DS. Thermodynamic approach to quantify human stress levels using an Objective Stress Index (OSI). *Applied Psychophysiology and Biofeedback* 1998, 23 (2), 110-111.
198. **Palsson OS**, Burnett CK, Meyer K, Whitehead WE. Hypnosis treatment for irritable bowel syndrome. Effects on symptoms, pain threshold and muscle tone. *Gastroenterology* 1997;112:A803
199. **Palsson OS**, Wickramasekera, IE, Rutledge C, Davies M, Downing B. Social desirability, repression, and finger temperature. *Applied Psychophysiology and Biofeedback* 1997;22(2):143.
200. **Palsson OS**, Taub E., Cook III EC, Burnett CK, McCommons JJ, Whitehead, WE. Validation of Rome criteria for functional gastrointestinal disorders by factor analysis. *American Journal of Gastroenterology* 1996, 91(9):2000.
201. **Palsson, OS**, Morteau O, McCommons JJ, Bozyski EM, Woosley JT, Sartor, RB, Whitehead WE. Vasoactive intestinal peptide is elevated in irritable bowel syndrome. *Gastroenterology* 1996, 109:A730.
202. **Palsson, OS**, Davidoff, A., Crowell, MD, Burnett, CK, Whitehead WE. Psychological functioning in irritable bowel syndrome: Role of sexual abuse history. *Gastroenterology* 1996,109;A729.
203. **Palsson OS**, Morteau O, McCommons JJ, Bozyski EM, Woosley JT, Sartor RB, Whitehead WE. Is mucosal inflammation present in irritable bowel syndrome? *Gastroenterology* 1996, 109:A730.
204. **Palsson OS**, McCommons JJ, Burnett CK, Bradley LA, Whitehead WE. Relationship between bowel sensations: Pain, urge to defecate and rectal fullness in irritable bowel syndrome (IBS) patients and healthy subjects. *Gastroenterology* 1995, 108:A663.
205. **Palsson OS**, Wickramasekera IE, Pope A. The psychological and psychophysiological effects of stress reduction via group hypnosis. *Psychological Hypnosis Bulletin*, Spring 1993: 3-5.

206. Wickramasekera IE, **Palsson OS**. (1991). Pilot study of psychological and physiological responses to exposure to pictures of dead bodies and body parts. *Proceedings of the 22nd Annual Meeting of the Association for Applied Psychophysiology and Biofeedback*, 1991:327-328.

D. AUDIO MATERIALS

Palsson, O.S. (2001). **Hypnosis Home Treatment Program for IBS**. A 5-CD set with an instruction booklet.

Palsson, O.S. (2010). **Hypnosis Home Treatment Program for Functional Chest Pain**. 8-session audio treatment program on MP3 players.

GRANTS

2019-2020. Co-investigator, Loyola Medicine Intramural Grant. Self Administered Gut Directed Hypnotherapy for Functional Dyspepsia (PI: S Kinsinger)

2018-2020. Co-investigator, Allergan Pharmaceuticals grant A17-174 Treatment of Diarrhea - Associated Fecal Incontinence with Eluxadoline. (PI: WE Whitehead).

2017-present. Principal Investigator, Glycom, Inc. multi-center trial "Real-world perception of tolerability and bowel function effects of fuco-n-tetraose in IBS patients".

2016-2018. Principal Investigator, Rome Foundation Contract 17-0957 "Global Survey of the Epidemiology of the Functional GI Disorders (FGIDs)".

2016-2020, Co-investigator, Department of Defense/Henry Jackson Foundation, Targeted Alteration of Dietary Omega-3 and Omega-6 Fatty Acids for the Treatment of Post-Traumatic Headaches. (PI: D Mann)

2013-2018. Co-investigator, National Center for Complementary & Alternative Medicine grant R01 AT007813-01A "Clinical and Metabolic Effects of Altering n-3 and n-6 Fatty Acids in Migraine (RCT)". (PI: D Mann).

2012-2017. Co-investigator, NIMH grant R01-MH093432-01 "Social Cognition Psychometric Evaluation (SCOPE)". (PI: AE Pinkham)

2013-2015. Co-investigator, NIH NIDDK grant 1R21DK096545-01A1 "Website for Self-Management of Fecal Incontinence" (PI: WE Whitehead)

2012-2015. Co-investigator, Agency for Healthcare Research and Quality grant R01 HS018695 "Conservative treatment of fecal incontinence in the elderly: Effectiveness trial" (PI: WE Whitehead)

2014-2015. Co-investigator, Takeda Pharmaceuticals grant 14-1503 "Serum markers for visceral hypersensitivity in IBS" (PI: MA van Tilburg)

2013-2014. Co-investigator, ONO Pharma USA Inc. grant 13-4315 "A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects with Diarrhea-Predominant Irritable Bowel Syndrome" (PI: L Gangarosa).

2012-2014. Co-investigator, Salix Pharmaceuticals grant 12-4519 "Reducing Barriers to the Diagnosis and Treatment of Fecal Incontinence" (PI: WE Whitehead)

2008-2013. Co-investigator, NIDDK grant RO1 DK31369 "Psychophysiology of IBS" (PI: WE Whitehead)

2011-2012. Co-investigator, Takeda Pharmaceuticals North America, "Interactive Chat Room on Functional GI and Motility Disorders". (PI: WE Whitehead)

2007-2011. Co-investigator on subcontract, NIH grant 1R01HD050345-01A2 "Psychosocial Intervention for Children with IBD" (PI: WE Whitehead)

2008-2010. Co-investigator, McNeil Consumer Health grant "Diarrhea Prevention (DIP) Study" (PI: WE Whitehead)

2009-2010 Co-investigator, Takeda Pharmaceuticals North America, Inc. grant "Improving Physician Communication and Patient Education with Innovative and Interactive Learning Methods". (PI: WE Whitehead)

2007-2010. Co-investigator, Takeda Pharmaceuticals North America, Inc. grant "Development of a Questionnaire to Measure Hypervigilance for Visceral Pain" (PI: WE Whitehead)

2007-2010. Co-investigator, Takeda Pharmaceuticals North America, Inc. grant "Lubiprostone Effects on Visceral Pain Sensitivity" (PI: WE Whitehead)

2006-2010. Co-investigator (S Gaylord is PI) of R21 AT3619, "Mindfulness treatment of irritable bowel." (PI: S Gaylord)

2008-2009. Co-investigator of McNeil Consumer Health contract titled, "Characterization of IBS symptom episodes." (PI: WE Whitehead)

2006-2008. Co-investigator of Novartis Pharmaceuticals contract titled, "CONQUEST: Questionnaire Study of Chronic Constipation." (PI: WE Whitehead)

2004-2009. Co-investigator and DATA Core Director, NIH infrastructure grant R24 DK067674 titled, "Gastrointestinal Biopsychosocial Research Center." (WE Whitehead and DA Drossman co-PIs)

2004-2005. Co-investigator of Novartis Pharmaceuticals contract entitled, "Validation of The Bloating Diagnostic Questionnaire and the Bloating Severity Questionnaire." (PI: WE Whitehead)

2003-2004. Co-investigator of Novartis Pharmaceuticals contract entitled, "Definition of IBS alternators." (PI: WE Whitehead)

2002-2004. Co-investigator of Novartis Pharmaceuticals contract entitled, "Evaluation of SERT gene polymorphisms and serotonin levels in IBS subgroups." (PI: WE Whitehead)

2002-2003. Co-investigator of Novartis Pharmaceuticals contract entitled, "Identifying patients with functional dyspepsia from medical records." (PI: WE Whitehead)

2001-2003. Co-investigator of Novartis Pharmaceuticals contract entitled, "Prospective study of the diagnosis and treatment of IBS in primary care and GI specialty clinics." (PI: WE Whitehead)

1998-2000. Principal investigator, National Aeronautics and Space Administration (NASA) "Contract for clinical trials of EAST neurofeedback game innovation technology"

1998-2000. Principal investigator, National Aeronautics and Space Administration (NASA) "Stress counter-response training via physiological self-regulation during flight simulation"

1997-1999. Principal investigator, Eastern Virginia Medical School Institutional Research Grant "Effects of hypnosis treatment on psychophysiology and vasoactive intestinal peptide in irritable bowel syndrome".

PATENTS

U.S. Patent #8,062,129. Pope & Palsson. **Physiological User Interface For a Multi-User Virtual Environment**. Co-inventor: Alan T. Pope, Ph.D., NASA Langley Research Center.

U.S. Patent #8,628,333 Prinzel III et al. **Method and apparatus for performance optimization through physical perturbation of task elements**. Co-inventors: Lawrence J. Prinzel, Ph.D., Alan T. Pope, Ph.D., Marsha Turner, M.S.

U.S. Patent #6,450,820. Palsson et al. **A Method of Encouraging Physiological Self-Regulation Through Modulation of an Operator's Control Input to a Video Game or Training Simulator"**. Co-inventors: Alan T. Pope, Ph.D., Randall L Harris, Sr, NASA Langley Research Center.

Two additional patents pending.

ORAL PRESENTATIONS AT NATIONAL SCIENTIFIC MEETINGS

June 3, 2018. **Palsson OS**, Heymen S, Busby-Whitehead J, Twist S, Whitehead WE. **Six-Week Internet Self-Help Intervention Reduces Symptom Episodes by 50% or More in the Majority of Individuals with Fecal Incontinence: A Pilot Study.** Annual Meeting of the American Gastroenterological Association, Washington DC.

August 25, 2018. **Achieving reliable success with hypnosis for irritable bowel syndrome by using standardized evidence-based treatment: How to treat patients most effectively with the North Carolina Protocol.** XXI World Congress of Clinical & Medical Hypnosis, Montreal, Canada.

October 17, 2016. **Rome IV and Rome III Irritable Bowel Syndrome in the US, Canada and the United Kingdom.** European Gastroenterology Week, Vienna, Austria.

August 28, 2016. **Rome IV and Rome III Functional Dyspepsia in the US, Canada and United Kingdom.** Federation for Neurogastroenterology and Motility International Scientific Meeting, San Francisco, CA.

October 2015. **Constipation symptoms in the U.S. general population: Results from the Rome Normative Gastrointestinal Symptoms Survey (RNGSS).** Symposium presentation, European Gastroenterology Week, Barcelona, Spain.

May 2014. **Mindfulness Meditation Has Long-Term Therapeutic Benefits in Women With Irritable Bowel Syndrome (IBS): Follow-Up Results From a Randomized Controlled Trial.** Presented at Digestive Disease Week 2014, Chicago, IL.

March 12, 2012. **The Advantages and Limitations of Standardized Clinical Hypnosis Treatment: When, why and how to develop and use scripted treatment protocols.** Invited presentation at the Annual Meeting of the American Society of Clinical Hypnosis, Charlotte, NC.

August 6, 2011. **Hypnosis treatment of Functional Gastrointestinal Disorders.** Presentation at the 119th Annual Convention of the American Psychological Association, Washington, DC.

March 7, 2011. **The Nationwide IBS Hypnosis Outcomes Project (NIHOP).** Presentation in a symposium titled "New developments in gut hypnosis research using standardized protocols", at the Annual Meeting of the American Society of Clinical Hypnosis, Las Vegas, NV.

March 2008. **Lessons from the Gut.** Invited presentation at the Annual Meeting of the American Society of Clinical Hypnosis, Chicago, IL.

May 23, 2006. **Coexistence of functional gastrointestinal disorders with other chronic visceral and somatic conditions.** Symposium presentation at the Annual Meeting of the American Gastroenterological Association. Los Angeles, CA.

March 25, 2006. **Hypnosis for gut problems: What we know, and future directions.** Invited presentation at the Annual Meeting of the American Society of Clinical Hypnosis, Orlando, FL.

May 17, 2005. **Education and reassurance affect satisfaction with care, health care utilization and clinical outcomes among new functional bowel disorder (FBD) patients.** Authors: Palsson OS, Levy RL, Von Korff, M, Feld AD, Turner MJ, Whitehead WE. Annual Meeting of the American Gastroenterological Association. Chicago IL.

April 21, 2005. **Biofeedback for Pelvic Floor Disorders and Incontinence.** Presentation in a full-day Science Forum on "Mind-Body Medicine: Improving Our Health and Performance". Washington, DC.

March 9, 2005. **Psychological treatments for functional gastrointestinal disorders.** Presentation at the Sixth International Symposium for Functional Gastrointestinal Disorders. Milwaukee, Wisconsin.

May 18, 2004. **Psychological symptoms do not predict symptom improvement in standard medical care for irritable bowel syndrome.** Research Forum presentation at the Annual Meeting of the American Gastroenterological Association. New Orleans, MO.

March 28, 2003. **Functional gastrointestinal disorders in primary care.** Symposium presentation at the 34th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback. Jacksonville, FL.

March 28, 2003. **The coming dissemination of biofeedback into society.** Symposium presentation at the 34th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback. Jacksonville, FL.

March 22, 2002. **Physiological findings on the High Risk Model of Threat Perception.** Symposium Presentation at the 33rd Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Las Vegas, NV.

March 31, 2001. **Neurofeedback videogame ADHD technology: Results of the first concept study.** Presentation in a symposium titled "The future of biofeedback: Fun and games?" at the 32nd Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Raleigh, NC.

March 30, 2001. **Treatment of a patient with irritable bowel syndrome, TMJ, headaches and back pain.** Presentation in a symposium at the 32nd Annual Meeting of Association for Applied Psychophysiology and Biofeedback, Raleigh, NC.

March 24, 2001. **Hypnosis treatment for irritable bowel syndrome: Research on efficacy and mechanism.** Presentation in a symposium at the 43rd Annual Meeting of the American Society for Clinical Hypnosis. Reno, Nevada.

August 2000. **Absorption and immune system competence.** Paper presented at the 108th Annual Convention of the American Psychological Association, Washington, D.C. Co-author: Stephanie L. Reavis, B.S.

August 2000. **Humor in cinema as hypnosis.** Paper presented at the 108th Annual Convention of the American Psychological Association, Washington, D.C. Co-author: Marcia E. Walker, M.A.

August 2000. **Physiological findings relating to the High Risk Model of Threat Perception.** Paper presented at the 108th Annual Convention of the American Psychological Association, Washington, D.C.

May 21, 2000. **Hypnotherapy for irritable bowel syndrome: Symptom improvement and autonomic nervous system effects.** Research Forum presentation, Annual Meeting of the American Gastroenterological Association, San Diego, CA.

March 31, 2000. **The EVMS Protocol: Automated and norm-referenced psychophysiological assessment.** Paper presented in a symposium titled "Psychophysiological profiling: A basic tool in clinical practice" at the 31st Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Denver, CO.

April 1, 2000. **Quantitative electroencephalographic (QEEG) activity, health history and emotional distress.** Paper presented at the 31st Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Denver, CO. Co-author: Jana Nussen, M.A.

April 2, 2000. **Psychological traits modulating threat perception and immune system competence.** Citation award paper presented at the 31st Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Denver, CO. Co-author: Stephanie L. Reavis, M.S.

February, 2000. **"Frontiers of hypnosis and psychosomatic medicine"**. Keynote address, Annual Meeting of the American Society of Clinical Hypnosis. Baltimore, MD.

June 28, 1999. **"Thermal biofeedback: Clinical applications and potential for aviation safety"**. Invited paper presented at the 33rd Annual Thermophysics Conference of the American Institute of Aeronautics and Astronautics. Norfolk, VA.

April 10, 1999. **"Psychophysiological characteristics of patients with irritable bowel syndrome"**. Paper presented at the 30th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback. Vancouver, Canada.

April 10, 1999. **"Gender matters: Psychophysiological data from ninety healthy men and women"**. Citation award paper presented at the 30th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback. Vancouver, Canada.

April 10, 1999. **"Stress counter-response training of pilots via instrument functionality feedback"**. Paper presented at the 30th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback in a symposium titled "New methods in biofeedback delivery: NASA innovations from aerospace to inner space". Vancouver, Canada.

April 10, 1999. **"New ways to deliver biofeedback"**. Paper presented at the 30th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback in a symposium titled "New methods in biofeedback delivery: NASA innovations from aerospace to inner space". Vancouver, Canada.

August 18, 1998. **"Effects of absorption on subjective and objective physical stress"**. Paper presented at the 106th Annual Convention of the American Psychological Association. San Francisco, CA. Co-Author: Brenda Downing, M.S.

August 18, 1998. **"Hypnosis and the gastrointestinal tract"**. Paper presented at the 106th Annual Convention of the American Psychological Association. San Francisco, CA.

April 5, 1998. **Psychological modulators of cardiovascular reactions to cognitive stress.** Award paper presentation at the 29th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback. Orlando, Florida. Co-Authors: S. Margaret Davies and Brenda K. Downing, M.S.

April 4, 1998. **"When slow is low: Low theta brainwave amplitudes and physical stress symptoms"**. Paper presented in a symposium titled "Spirit, Mind, Healing, and the EEG" at the 29th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback. Orlando, Florida. Co-authors: Ian Wickramasekera, Ph.D., and Brenda Downing, M.S.

April 4, 1998. **"Effective management of chronic irritable bowel syndrome in primary care patients"**. Presentation in a symposium titled "Applied Psychophysiology in Primary Care", at the 29th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback. Orlando, Florida.

April 2, 1998. **The relationship between an Objective Stress Index (OSI) and stress-related physical symptoms.** Presentation in the "Speaker's Corner" program section at the 29th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback. Orlando, Florida. Co-authors: Satish C. Boregowda, M.E., and Brenda K. Downing, M.S.

May 13, 1997. **"Hypnosis treatment for irritable bowel syndrome. Effects on symptoms, pain threshold, and muscle tone"**. Research forum presentation at the Annual Meeting of the American Gastroenterological Association. Washington, DC.

August, 1996. "**Somatization and psychosocial characteristics in irritable bowel syndrome patients**". Paper presented in a symposium titled "Somatization and psychosocial factors in medical patients". 104th Annual Convention of the American Psychological Association, Toronto, Canada.

August, 1996. "**The psychophysiological effects of hypnosis treatment for irritable bowel syndrome**". Paper presented in a symposium titled "The psychophysiology of the hypnotic response: Results from hardcore experiments". 104th Annual Convention of the American Psychological Association, Toronto, Canada.

May 17, 1995. "**Relationship between bowel sensations: Pain, urge to defecate and rectal fullness in irritable bowel syndrome (IBS) patients and healthy subjects**". Research forum presentation at the Annual Meeting of the American Gastroenterological Association. San Diego, California.

March 7, 1994. "**A comparative study of stress risk and psychophysiology in patients in a behavioral medicine clinic and college students under stress**". Symposium presentation at the 25th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback. Atlanta, Georgia.

March 27, 1993. "**Psychophysiological effects in a study of stress-reduction hypnosis**". Symposium presentation at the 24th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback. Los Angeles, California.

TEACHING IN NATIONAL AND REGIONAL CME AND CEU COURSES

August 5, 2017. **Live demonstrations from NYU Langone Medical Center: Delivery of hypnosis for refractory gastrointestinal disorders**. Presenter and moderator. American Neurogastroenterology and Motility Society 12th Postgraduate Course: Gastrointestinal Motility and Neurogastroenterology in Clinical Practice. New York City.

March 13, 2016. **How to Create Your Own Reliably Effective Hypnosis Protocols for Chronic Physical Symptoms**. Four-hour advanced workshop at the Annual Meeting of the American Society of Clinical Hypnosis, St. Louis, MO.

March 24, 2014. **Crafting Effective Therapeutic Suggestions and Metaphors for Treatment of Gastrointestinal Symptoms**. Four-hour advanced workshop at the Annual Meeting of the American Society of Clinical Hypnosis, San Diego, CA.

November 2, 2013. **Hypnosis Treatment: What is it, who benefits, and how well does it work?** Presentation in an AHEC CME Symposium titled "How to Treat IBS Effectively". Chapel Hill, NC.

November 2, 2013. **How to make a successful referral for psychological treatment**. Presentation in an AHEC CME Symposium titled "How to Treat IBS Effectively". Chapel Hill, NC.

March 20, 2012. **Designing Hypnotherapy Studies on the Brain-Body Interface: IBS as Model Illness**. One-day advanced workshop presented at the Annual Meeting of the American Society of Clinical Hypnosis, Charlotte, NC. Co-Presenters: Douglas A. Drossman, M.D., Eva Szigethy, M.D., Ph.D.

March 7, 2011. **Crafting Effective Therapeutic Suggestions and Metaphors for Treatment of Gastrointestinal Symptoms**. 2 ½ hour advanced workshop at the Annual Meeting of the American Society of Clinical Hypnosis, Las Vegas, NV.

March 9, 2008. **Getting to the Gut**. Presentation at the Annual Meeting of the American Society of Clinical Hypnosis, Chicago, IL.

April 2, 2005. **“Treating refractory IBS”**. Group discussion leader, break-out session at the UNC Annual Update in Gastroenterology and Hepatology, Chapel Hill, North Carolina.

November 11-14, 2004. **Hypnosis Treatment for Functional Gastrointestinal Disorders**. A 3 ½ day course for health professionals, Research Triangle Park, NC. Instructor and course director.

October 10, 2003. **Non-Pharmacologic Treatments for Irritable Bowel Syndrome**. A 3-hour seminar for the North Carolina Biofeedback Society. Chapel Hill, NC.

April 7, 2003. **Treating gastrointestinal disorders with hypnosis**. Advanced one-day workshop, 45rd Annual Meeting of the American Society for Clinical Hypnosis. Alexandria, Virginia.

January 25-26, 2002. **Trauma, Fear and Loss and in Troubled Times**. Two-day advanced regional hypnosis workshop by the American Society for Clinical Hypnosis. Charlotte, North Carolina. Workshop Chair: Claire Frederick, M.D.

March 25, 2001. **Treating gastrointestinal disorders with hypnosis**. Advanced one-day workshop, 43rd Annual Meeting of the American Society for Clinical Hypnosis. Reno, Nevada.

October 2000. **How to interface applied psychophysiology, biofeedback, and psychotherapy in primary care medicine and complementary medicine settings**. Three-day continuing education workshop sponsored by the Association of Applied Psychophysiology. Workshop director: Ian E. Wickramasekera, Ph.D.

June 5, 2000. **Introduction to medical uses of hypnosis**. A 2 ½ hour continuing education workshop for family physicians. Annual Family Medicine Review Course, Virginia Beach, Virginia. Co-presenter: S. Margaret Davies, M.D.

March 31, 2000. **Achieving effective detection, diagnosis and intervention for common psychosocial and psychophysiologic problems in primary care**. A half-day workshop to be presented at the 31st Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Denver, CO.

October 8-10, 1999. **Introductory training course in clinical hypnosis**. A 20-hour training course for health professionals presented by the Virginia Hypnosis Society and approved by the American Society for Clinical Hypnosis. Norfolk, Virginia. Co-presenters: Vicki Caminer, Psy.D., Richard Griffin, Psy.D., Donald Lynch, M.D., Alan T. Pope, Ph.D.

September 21-25, 1999. **How to interface applied psychophysiology, biofeedback, and psychotherapy in primary care medicine and complementary medicine settings**. Three day continuing education workshop sponsored by the Association of Applied Psychophysiology and Biofeedback. Marco Island, FL. Co-instructors: Ian E. Wickramasekera, Ph.D., Terence C. Davies, M.D., Steven Baskin, Ph.D., John Arena, Ph.D., Alan Glaros, Ph.D.

June 9, 1999. **The most common DSM-IV problems in primary care: Effective diagnosis and intervention**. A 2 ½ hour continuing education workshop for family physicians. Annual Family Medicine Review Course, Virginia Beach, Virginia. Co-presenter: S. Margaret Davies, M.D.

November 6, 1998. **Introduction to clinical hypnosis**. One-day workshop at the Annual Meeting of the Virginia Psychological Association. Richmond, VA. Co-presenter: Richard B. Griffin, Psy.D.

October 15-17, 1998. **How to interface applied psychophysiology, biofeedback, and psychotherapy in primary care medicine and complementary medicine settings**. Three day continuing education workshop sponsored by the Association of Applied Psychophysiology and Biofeedback. Scottsdale, Arizona. Co-instructors: Ian E. Wickramasekera, Ph.D., Terence C. Davies, M.D., Steven Baskin, Ph.D.

June 8, 1998. "**Effective application of the biopsychosocial model: A joint venture**". Presentation in the Annual Family Medicine Review Course, Virginia Beach, Virginia. Co-presenter: S. Margaret Davies, M.D.

June 7, 1998. "**Psychophysiology: Putting the mind-body relationship to work**". Presentation in the Annual Family Medicine Review Course, Virginia Beach, Virginia.

June 6, 1998. "**Efficient psychosocial screening: What you ask is what you get**". Two-hour workshop at a National Symposium titled "Behavioral Medicine: Bridging the mind-body gap in patient care", Virginia Beach, VA. Co-presenters: Margaret Davies, MD, and Gregory Anderson, Ph.D.

October 17, 1997. "**Introduction to clinical hypnosis**". Two-hour workshop at the Annual Meeting of the Virginia Psychological Association. Hampton, VA. Co-presenter: Richard B. Griffin, Psy.D.

Aug. 9, 1996. "**Treating somatic symptoms effectively with hypnosis and psycho-physiological methods**". American Psychological Association Continuing Education Program. One-day CE workshop for psychologists at the APA Annual Convention in Toronto. Co-instructors: Ian Wickramasekera, Ph.D., ABPP, ABPH; Richard B. Griffin, Psy.D.

CO-AUTHORSHIP OF WORK PRESENTED AT NATIONAL AND INTERNATIONAL MEETINGS BY OTHERS

Garland, E.L., Gaylord, S.A., Palsson, O., Faurot, K., Mann, J.D., & Whitehead, B. (2012, April). **Mindfulness Training Targets Cognitive-Affective Mechanisms in Irritable Bowel Syndrome by Modulating Emotional Processing of Pain Sensations**. Society for Behavioral Medicine, 2012, New Orleans.

Garland, E.L., Gaylord, S.A., Palsson, O., Faurot, K., Mann, J.D., & Whitehead, W. (2011, January 14). **Mindfulness training targets cognitive and affective mechanisms to reduce illness severity and improve quality of life among women with irritable bowel syndrome**. Society for Social Work and Research, Tampa, FL.

Gaylord, S., Palsson, O., Faurot, K., Garland, E., Coble, B., Mann, D., & Whitehead, B. (2009, May 12). **Dispositional mindfulness is associated with psychological symptoms accompanying irritable bowel syndrome**. Poster presentation at the North American Research Conference on Complementary & Integrative Medicine, Minneapolis, MN.

Moss, D., Sella, G. E., Andrasik, F., Donaldson, S., Lehrer, P., Palsson, O., Peper, E., & Serman, M. B. (2004, December). **[Medycyna umysłu i ciała, biofeedback oraz powszechnie problemy zdrowotne]**. Mind-body medicine, biofeedback, and common health disorders. Presentation to the International Symposium of Noo-Logotherapy—In Centenary of Viktor Frankl's Birth, Noo-Psychosomatika (Mind-Body Medicine Division), Catholic University, Lublin, Poland.

Nevin, S.T., Ball, J.D., Palsson, O., Ware, J.C., Hartmann, K., & Winstead, B. (2003, August). **An objective method for detection of ADHD in children**. Poster presented at the 111th Annual Convention of the American Psychological Association, Toronto, Canada.

Palsson, O.S., Feld, A.D., Levy R.L., Von Korff, M., Barghout V., Turner M.J., Whitehead, W.E. (2003). **Comparison of irritable bowel syndrome (IBS) patients in gastroenterology and primary care clinics**. Paper presented at the Annual Meeting of the American Gastroenterological Association. May 17, 2003, Orlando, FL.

Pope, A.T. & Palsson, O.S. (2001). **Helping videogames "rewire" our minds**. Invited Paper, 2001 Arts & Humanities in Public Life Conference: "Playing by the Rules: The Cultural Policy Challenges of Video Games". University of Chicago, October 26 & 27, 2001.

deBeus, R.J., Palsson, O.S., Pope, A.T., Ball, J.D., & Turner, M.J. (2001). **Comparison of Videogame & Standard EEG Biofeedback with AD/HD Children: Results of the First Concept Study**. Proceedings of the 9th Annual Society for Neuronal Regulation Conference, Oct 27-30, 2001.

Stewart, D., Prinzel, A.T., Pope, A.T., & Palsson, O.S. (2001). **Stress Counter-response Training: Flight Simulation ANS Biofeedback Training for Pilots**. Presented at the 2001 Annual Meeting of the Association for Applied Psychophysiology and Biofeedback Meeting, Raleigh-Durham, NC.

Jones, K.R., Whitehead, W.E., Overton C, Bradshaw, B., Palsson, O.S., & Drossman, D.A. (2001). **Length of verbal stimuli affects selective attention tests**. Poster presentation E-161 at the 22nd Annual Meeting of the Society of Behavioral Medicine. Seattle, WA.

Cubic B.A., Bluestein, D.A., Downing, B.K., Palsson, O.S., & Stroup, A. (1997). **"The impact of on-site behavioral training on family practice residents"**. Poster presented at the 31st Association for the Advancement of Behavior Therapy Convention: Miami Beach, FL.

OTHER PROFESSIONAL PRESENTATIONS

April 20, 2016. **"Population Survey of Functional Gastrointestinal Disorders in the U.S., Canada and the U.K. Using the New Rome IV Criteria"**. Presentation in the weekly epidemiology meeting in the Division of Gastroenterology and Hepatology at UNC-Chapel Hill.

June 22, 2014. Presentation titled **"Effective psychological treatments (CBT & Hypnosis) for GI Symptoms"**. Expert Update on Treatments for Functional GI Disorders: A Symposium for Patients. Washington, DC.

June 23, 2014. Taught a two-hour workshop for FGID patients titled. **"How Hypnosis Treatment Can Help Your Gastrointestinal Symptoms"** Expert Update on Treatments for Functional GI Disorders: A Symposium for Patients. Washington, DC.

November 1, 2013. Presentation titled **"Population prevalence of functional GI symptoms in adults: Implications for the diagnosis of FGIDs"**. Annual Research Day of the UNC Center for Functional GI & Motility Disorders. Chapel Hill, NC.

November 1, 2013. Presentation titled **"Diary studies of the variability of bowel habits and symptoms in IBS: The relationship between pain and stool consistency"**. Annual Research Day of the UNC Center for Functional GI & Motility Disorders, 2013

June 23, 2012. **"Hypnosis Treatment for Irritable Bowel Syndrome"**. Presentation in an educational symposium titled "Expert Update on Treatments for Functional GI Disorders: A Symposium for Patients". Chapel Hill, NC.

January 15, 2012. **"Empirically defining symptom episodes in IBS"**. Annual Research Day Symposium, Center for Functional GI and Motility Disorders. Chapel Hill, NC.

September 29, 2009. **Hypnotherapy**. A one-hour lecture in the UNC-Chapel Hill School of Medicine course "Principles and Practice of Complementary and Alternative Medicine". Chapel Hill, NC.

September 26, 2009. **Natural History of Irritable Bowel Syndrome Episodes**. Annual Research Day Symposium, Center for Functional GI and Motility Disorders. Chapel Hill, NC.

September 25, 2009. **Nationwide Effectiveness Trial of Hypnosis for IBS**. Annual Research Day Symposium, Center for Functional GI and Motility Disorders. Chapel Hill, NC.

September 25, 2009. **Hypnosis for Functional Heartburn**. Annual Research Day Symposium, Center for Functional GI and Motility Disorders. Chapel Hill, NC.

October 25, 2008. **Hypnotherapy for Functional GI Disorders**. Presentation in a Patient Symposium hosted by the UNC Center for Functional GI and Motility Disorders. Chapel Hill, NC.

October 4, 2008. **CONQUEST Study: Impact of Constipation on Quality of Life and Healthcare Costs**. Annual Research Day Symposium, Center for Functional GI and Motility Disorders. Chapel Hill, NC.

October 4, 2008. **Characterization of IBS Symptom Episodes**. Annual Research Day Symposium, Center for Functional GI and Motility Disorders. Chapel Hill, NC.

September 12, 2008. **Hypnotherapy**. A one-hour lecture in the UNC-Chapel Hill School of Medicine course "Principles and Practice of Complementary and Alternative Medicine". Chapel Hill, NC.

September 28, 2007. **Investigating the Role of Comorbidity in Irritable Bowel Syndrome**. Presentation at the Annual Research Day Symposium, Center for Functional GI and Motility Disorders. Chapel Hill, NC.

September 7, 2007. **Hypnotherapy**. A one-hour lecture in the UNC-Chapel Hill School of Medicine course "Principles and Practice of Complementary and Alternative Medicine". Chapel Hill, NC.

September 11, 2006. **Hypnotherapy**. A one-hour lecture in the UNC-Chapel Hill School of Medicine course "Principles and Practice of Complementary and Alternative Medicine". Chapel Hill, NC.

June 17, 2006. **Comorbidity and somatization scales**. Presentation at the Annual Research Day Symposium, Center for Functional GI and Motility Disorders. Chapel Hill, NC.

June 17, 2006. **Development of bloating severity questionnaires**. Presentation at the Annual Research Day Symposium, Center for Functional GI and Motility Disorders. Chapel Hill, NC.

June 15, 2006. **Hypnosis for Functional GI disorders**. Presentation in a Patient Symposium hosted by the UNC Center for Functional GI and Motility Disorders. Chapel Hill, NC.

June 15, 2006. **Psychological treatments for functional GI disorders**. Facilitation of a break-out session at the UNC Center for Functional GI and Motility Disorders. Chapel Hill, NC.

June 2005. **Hypnosis treatment for IBS: The North Carolina model**. Presentation at the Annual Research Day Symposium, Center for Functional GI and Motility Disorders. Chapel Hill, NC.

October 18, 2004. **"Hypnosis treatment for Gastrointestinal Disorders"**. Family Medicine Grand Rounds, Department of Family Medicine, UNC-Chapel Hill, Chapel Hill, NC

July 16, 2004. **"Hypnosis treatment for Gastrointestinal Disorders"**. Program for Integrative Medicine, Chapel Hill, NC

June 12, 2004. **"Hypnosis treatment for Functional GI Disorders"**. Presentation in a Patient Symposium hosted by the UNC Center for Functional GI & Motility Disorders. Chapel Hill, NC

September 20, 2003. "**Irritable Bowel Syndrome: What We Know About It and What Psychologists Can Do About It**". Presentation at the 25th Anniversary Meeting of the Virginia Consortium Program in Clinical Psychology.

February 24, 2003. "**Gender Differences in Irritable Bowel Syndrome**". Preceptorship presentation for Novartis Pharmaceuticals Corp. Chapel Hill, NC.

February 25, 2003. "**Psychological Treatment of Irritable Bowel Syndrome**". Preceptorship presentation for Novartis Pharmaceuticals Corp. Chapel Hill, NC.

June 2002. "**Gender Differences in Irritable Bowel Syndrome**". Preceptorship presentation for Solvay Pharmaceuticals. Chapel Hill, NC.

June 2002. "**Psychological treatment of Irritable Bowel Syndrome**". Preceptorship presentation for Solvay Pharmaceuticals. Chapel Hill, NC.

January 17 2000. "**Biofeedback**". EVMS Radio Rounds. WHRO-FM Public Radio, Norfolk, Virginia.

January 18, 2000. "**Clinical Hypnosis**". EVMS Radio Rounds. WHRO-FM Public Radio, Norfolk, Virginia.

May 28, 1999. "**The chronic pain patient in psychotherapy**". A seminar for doctoral students in clinical psychology, Virginia Consortium Program in Clinical Psychology, Virginia Beach, Virginia.

April 29, 1999. "**Alternative medicine**". Invited presentation at the 58th Annual Meeting of the National Association for Practical Nurse Education and Service. Virginia Beach, VA.

October 28, 1998. "**Biofeedback: Mind over Matter**". Grand Rounds presentation, EVMS Department of Internal Medicine.

June 6, 1998. "**Mind-body medicine in the 21st Century: A sneak preview of new technologies and treatments**". Presentation at a National Symposium titled "Behavioral Medicine: Bridging the mind-body gap in patient care", Virginia Beach, VA. Co-presenter: Alan T. Pope, Ph.D.

May 8, 1998. "**Keeping stress from hurting your health**". A presentation to the Suffolk Rotary Club. Suffolk, VA.

April 7, 1998. "**Complementary medicine**". One-hour radio presentation on public radio WHRO-FM in the Hear/Say program. Co-presenter: Alan Doyle, D.O.

February 21, 1998. "**Psychophysiology: Putting the mind-body connection to work**". Presentation at the American Medical Association's Conference of Mid-Atlantic States. Norfolk, Virginia.

November 11, 1997. "**Overview of behavioral medicine programs for chronic headache, irritable bowel syndrome, and unsuccessful weight loss**". Invited dinner presentation, Tidewater Academy of Clinical Psychologists. Norfolk, Virginia.

October 16, 1997. "**How to keep stress from hurting your health**". Tidewater Delta Gamma Women's Alumni Organization. Virginia Beach, Virginia.

October 4, 1997. "**Biofeedback for pain management**". Presentation at the Annual Meeting of the Virginia Association of Nurse Anesthetists. Virginia Beach, Virginia Beach.

September 4, 1997. "**Biofeedback and the mind-body connection**". One hour presentation for the Women's Wisdom Circle, a support group for women who have had breast cancer. Norfolk, Virginia.

August 20, 1997. "**Your attitude and your health**". An invited presentation for the Kiwanis Club of Virginia Beach. Virginia Beach, Virginia.

June 17, 1997. "**Neurofeedback treatment for attention-deficit/hyperactivity disorder: status and future prospects**". Presentation in NASA/ODU/EVMS International Seminar on New Psychophysiological Treatments for Attention-Deficit/Hyperactivity Disorder. Old Dominion University. Norfolk Virginia.

May 20, 1997. "**Behavioral medicine techniques in the management of pain**". Invited presentation for residents in the EVMS Department of Physical Medicine and Rehabilitation".

March 20 and 27. "**Introduction to clinical hypnosis**". A two-part six-hour workshop for the residents in psychiatry. Eastern Virginia Medical School. Co-instructor: Richard B. Griffin, Psy.D.

February 20, 1997. "**Keeping stress from affecting your health**". Presentation open to the public, Eastern Virginia Medical School.

February 14, 1997. "**Behavioral medicine**". One-hour radio presentation on public radio WHRV-FM in the Hear/Say program. Co-presenters: Barbara A. Cubic, Ph.D., and Richard B. Griffin, Psy.D. Norfolk, Virginia.

February 8, 1997 "**Introduction to hypnosis in clinical practice**". Two-hour workshop at the EVMS Medical Students Annual Retreat. Nags Head, SC. Co-presenter: Angela Stroup, RN, MA.

Sept. 25 1996. "**Results of the functional GI disorders questionnaire study**". Gastroenterology pathophysiology conference, UNC-Chapel Hill Department of Medicine. Co-presenter: William E. Whitehead, Ph.D.

Apr. 18, 1996. "**Gastrointestinal neuropeptides in irritable bowel syndrome patients and healthy subjects**". Paper presented in the 1996 Research Competition of the Center for Gastrointestinal Biology and Disease. University of North Carolina at Chapel Hill.

Jan. 29, 1996. "**Munchhausen's syndrome? Review and case discussion**". Presentation in a seminar series for GI division medical and research staff. UNC Functional Gastrointestinal Disorders Center, Memorial Hospital, Chapel Hill. Co-presenters: William Harlan III, MD, and Charles K. Burnett, Ph.D., Dr.PH.

Oct. 25, 1995. "**Pain perception and psychological adjustment in irritable bowel syndrome: The relationship to abuse history**". Presentation in a seminar series for GI division medical and research staff. UNC Functional Gastrointestinal Disorders Center, Memorial Hospital, Chapel Hill. Co-presenter: William E. Whitehead, Ph.D.

Sept. 27, 1995. "**Autogenic training and hypnosis**". Presentation in a seminar series for GI division medical and research staff. UNC Functional Gastrointestinal Disorders Center, Memorial Hospital, Chapel Hill.

Aug.30, 1995. "**Psychological Approaches II: Psychological testing. Utility in the medical setting, appropriate referral questions, etc.**" Presentation in seminar series for GI division medical and research staff. UNC Functional Gastrointestinal Disorders Center, Memorial Hospital, Chapel Hill. Co-presenter: Charles K. Burnett, Ph.D., Dr.P.H.

April 12, 1995. "**Hypnosis treatment for irritable bowel syndrome: How does it work?**" Gastroenterology pathophysiology conference, UNC-Chapel Hill Department of Medicine.

March 15, 1995. "**Somatization II**". Presentation in seminar series for GI division medical and research staff. UNC Functional Gastrointestinal Disorders Center, Memorial Hospital, Chapel Hill.

Nov. 9, 16 & 23, 1994. "**Pain management I, II and III**". Presentations in seminar series for GI division medical and research staff. UNC Functional Gastrointestinal Disorders Center, Memorial Hospital, Chapel Hill.

Sept. 28, 1994. "**Hypnosis and irritable bowel syndrome**". Presentation in seminar series for GI division medical and research staff. UNC Functional Gastrointestinal Disorders Center, Memorial Hospital, Chapel Hill.

April 14, 1994. "**Stress reduction treatment by means of group hypnosis**". Invited lecture, Psychiatric Grand Rounds, Eastern Virginia Medical School, Norfolk, Virginia.

Nov. 29, 1993. "**Stress**". Invited presentation, Department of Health Education, University of Maryland at College Park. College Park, Maryland.

Nov. 6 & 10, 1992. "**Hypnosis and hypnotherapy**". Two-part presentation and clinical demonstration for the psychotherapy staff at the North Central Human Service Center. Minot, North Dakota.

July 25, 1992. "**Stress reduction via group hypnosis**". Invited presentation at the annual meeting of the Virginia Hypnosis Society. Norfolk, Virginia.

HONORS AND AWARDS

October 2016. **Fellowship Award, Rome Foundation**. For "notable service that has helped advance the mission and objectives of the Foundation". Awarded by the Rome Foundation.

March 2015. **The Hilgard Award for best hypnosis paper on historic topic**. Awarded by the American Journal of Clinical Hypnosis.

October 2009. **ACG Presidential Poster Award**. American College of Gastroenterology 71th Annual Scientific Meeting, San Diego, California.

September 2005. **Nomination and runner-up prize, NASA Commercial Invention of the Year Awards**. Shared award with Alan T. Pope and Randall L. Harris. Awarded by NASA.

March 2005. **Award of Merit, American Society of Clinical Hypnosis**. "For significant contributions demonstrating the efficacy of hypnotic interventions in psychophysiological disorders". 47th Annual ASCH Meeting, St. Louis, Missouri.

October 2003. **ACG Presidential Poster Award**. Awarded by the American College of Gastroenterology at the 65th Annual Scientific Meeting, Baltimore, Maryland.

March 2000. **Outstanding research paper award**. 31st Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Denver, Colorado. Co-author: Stephanie L. Reavis, M.S.

April 1999. **Outstanding research paper award**. 30th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Vancouver, Canada. Co-author: Brenda Downing, MS.

April 1999. **Presidential Service Award**, Association for Applied Psychophysiology and Biofeedback.

April 1998. **Outstanding research paper award**. 29th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Orlando, FL. Co-authors: Margaret Davies, MD, and Brenda Downing, MS.

April 1998. **Best research poster award.** 29th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Orlando, FL.

CURRENT PROFESSIONAL MEMBERSHIP

Member, American Society for Clinical Hypnosis

Member, American Gastroenterological Association

CURRENT PSYCHOLOGY LICENSES

Licensed Clinical Psychologist, Commonwealth of Virginia. License #0810-002518

Licensed Psychologist-Provisional, North Carolina. License #102116